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The complete recovery of injured skeletal muscle has posed a constant challenge for 
orthopaedic physician. Once injured, skeletal muscle is able to undergo regeneration from 
satellite cells; nevertheless, in the serious injured muscle, the formation of fibrosis often impedes 
effective muscle regeneration and resulted in an incomplete muscle healing. Therefore, to 
develop biological approaches to improve muscle healing, it is crucial to better understand the 
mechanisms of the skeletal muscle fibrosis.  
In the current studies, we found that myostatin (MSTN), a member of TGF-β family, 
plays a role in the formation of skeletal muscle fibrosis, besides the other putative fibrosis 
stimulator, TGF-β1. In vitro, MSTN directly stimulated the proliferation of fibroblasts and their 
productions of fibrotic proteins. In vivo, after laceration injury, gastrocnemius muscles of 
MSTN-/- mice showed less fibrosis and better muscle regeneration than wide-type (WT) 
counterparts. Considering MSTN as a therapeutic target of skeletal muscle healing, we found 
that inhibitors of MSTN, MSTN propeptide (MPRO) and follistatin, effectively blocked MSTN 
signaling and improved skeletal muscle healing after injured. We used adeno-associated virus 
(AAV)-mediated MPRO cDNA to successfully deliver MPRO in vivo and improve skeletal 
muscle healing of normal mice after laceration, and ameliorate dystrophic pathology of 
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mdx/SCID mice.  Furthermore, our results demonstrated FLST overexpression (FLST/OE) mice 
exhibited decreased fibrosis and increased muscle regeneration in injured skeletal muscle as 
compared to wild-type (WT) mice. Moreover, muscle progenitor cells (MPCs) isolated from 
MSTN-/- and FLST/OE mice significantly regenerated more myofibers than MPCs obtained 
from WT mice, when transplanted into dystrophic muscles.  
Collectively, our results suggested that MSTN directly stimulated fibrosis in the injured 
skeletal muscle; blocking MSTN signaling with MPRO or FLST improved skeletal muscle 
healing after laceration injury; blocking MSTN signaling in donor MPCs significantly enhanced 
the success of cell transplantation into dystrophic muscles. Our studies not only uncover some of 
the mechanisms implicated in skeletal muscle fibrosis and regeneration, and help the 
development of new therapeutic approach for promoting the healing of injured or diseased 
skeletal muscle, but also render a new sight of how to obtain robust genetically modified cell 
populations for cell therapy.  
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1.0  INTRODUCTION 
Although skeletal muscle injuries are extremely common, accounting for up to 30% of all sports-
related injuries, the treatments that are currently available are often conservative and ineffective 
such as RICE principle (rest, ice, compression, and elevation), non-steroid anti-inflammatory 
drugs (NSAIDs), therapeutic ultrasound, and hyperbaric oxygen. More and more evidence has 
shown that administration of NSAIDs delays inflammation and regeneration and increases 
fibrosis 1-5. Neither therapeutic ultrasound nor hyperbaric oxygen therapy has had beneficial 
effects on the final outcome of muscle healing 6, 7.  Injured muscle can undergo regeneration 
spontaneously from satellite cells, a reservoir of myogenic progenitor cells for the repair and 
maintenance of skeletal muscle, but the ensuing formation of fibrous scar tissue often impedes 
efficient muscle regeneration, resulting in incomplete healing 8, 9. As a result, previously injured 
muscle continues to show muscle atrophy or loss of function, including loss of muscle 
extensibility and strength. Moreover, there is significant morbidity associated with these injuries, 
such as the development of painful contractures and the increased risk for repeat injury, by and 
large as a result of extensive fibrosis.  
    To improve the healing of injured muscle, researchers have administered growth 
factors that can promote muscle regeneration, including insulin-like growth factor-1 (IGF-1), 
basic-fibroblast growth factor (bFGF), and nerve growth factor (NGF), to injured skeletal 
muscles 10-13. Treatment with such growth factors—particularly IGF-1—enhanced muscle 
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regeneration and strength to some extent; however, fibrosis still predominated and prevented 
complete recovery of the injured muscle. Injured muscle exhibits active muscle regeneration 
before the formation of thick and extensive connective tissue 9, 14, 15. However, many newly 
formed myofibers express not only desmin, a myogenic marker, but also vimentin, a fibroblast 
marker. Some of the regenerating myofibers are TGF-β1 positive as soon as 3 days after injury 
16. With the development of fibrosis, the vimentin- or TGF-β1-positive regenerating myofibers 
become smaller and gradually disappear, which ultimately are  replaced by mononucleated 
fibrotic cells and scar tissue 11, 16. Therefore, apart from the enhancement of muscle regeneration, 
the prevention of fibrosis is key effort to improve skeletal muscle healing.  
Transforming growth factor-β1 (TGF-β1) is a potent fibrogenic cytokine in many tissues 
and organs, including the lungs, kidneys, liver, heart, and skin 17-20. To date, it has been widely 
accepted that TGF-β1 is also associated with fibrosis in skeletal muscle 21-23. Elevated TGF-β1 
levels are observed in dystrophic skeletal muscle and shortly after skeletal muscle injury 16, 21-23. 
Research has shown that elevated expression of TGF-β1 accounts for the initiation and 
development of fibrosis in muscular dystrophies 21, 22. TGF-β1 has been proven to effectively 
induce myofibroblastic differentiation of fibroblasts both in vitro and in vivo, the induction of 
which is responsible for excessive accumulation of fibrous tissue 24, 25. Members of our research 
group have shown that TGF-β1 plays a significant role in both the initiation of fibrosis and the 
inducement of myofibroblastic differentiation of myogenic cells in the injured muscles 16, 26. The 
use of antifibrosis therapies such as TGF-β1 neutralizing antibody, interferon-gamma (IFN-γ), 
suramin, relaxin, decorin, or losartan can improve the healing of the injured muscles both 
histologically and physiologically 27-32; however, none of these approaches can completely 
prevent fibrosis, and the precise mechanisms of fibrosis remain unclear. For instance, it warrants 
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further investigation whether TGF-β1 acts along or requires interaction with other molecules 
during the development of muscle fibrosis. It is likely that other molecules also positively 
regulate fibrosis. In this project, we have been engaging in searching potential molecules that 
participates in the skeletal muscle fibrosis, helping better understand mechanisms involved in the 
fibrosis of the injured skeletal muscle, and developing novel biological approaches to the injured 
skeletal muscles based on new therapeutic target that we have identified in the current project. 
1.1 LITERATURE REVIEW 
1.1.1 Wound Healing 
Muscle injury and repair have been widely investigated. Muscle injuries occur after either direct 
trauma (e.g., rupture or laceration) or indirect trauma (e.g., excessive stress, contusion, or strain). 
Regardless of the type of injury, injured muscles undergo a sequential series of events during the 
wound healing process including: inflammatory response, necrosis, muscle regeneration, and 
remodeling 8, 9, 33, 34. Immediately after injury, the inflammation process is initiated through the 
hematoma formation resulting from ruptured blood vessels within the muscle tissue. 
Simultaneously, the damaged muscle is subjected to degeneration and necrosis as a result of the 
disintegration of the muscle membrane. A leak in the muscle membrance leads to the activation 
of intracellular autodegradative pathways by an influx of calcium and the cytotoxin secreted by 
invading neutrophils. Numerous inflammation cells also invade the injured site during this early 
phase. The repair phase begins with phagocytosis of damaged tissue. Normally quiescent satellite 
cells known as myogenic precursor cells are activated. During the removal of tissue debris, 
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activated satellite cells (myoblasts) withdraw from their self-renewal cycle, readily differentiate, 
and either fuse with each other (grey arrow) to form multinucleated myotubes or fuse with pre-
existing myofibers (white arrowhead) 14, 33, 35, 36 (Figure 1.1; Figure 1.2). In the meantime, 
extracellular matrix (ECM) components are synthesized by fibroblasts, and capillary ingrowth is 
initiated. During the remodeling phase, regenerating myofibers undergo maturation and scar 
tissue remodels, events that lead to functional recovery of the injured muscle 34. During skeletal 
muscle healing, an appropriate amount of ECM must be present to serve as a scaffold for fusing 
myoblasts 35, 37 and for the transmission of loads across the tissue defect. However, muscle 
regeneration and the deposition of ECM are concomitant and competitive events. Excessive 
connective tissue can form a dense mechanical barrier 38 that interrupts the milieu that is 
necessary for myofiber growth and prevents regenerated muscle myofibers from growing and 
elongating. Fibrosis is characterized by an excessive number of abnormally active fibroblasts,  
the excess accumulation of collagen, disorganized ultrastructural morphology of the connective 
tissue, and an abnormal proportion of matrix components 39.  
        SZ      RZ    CZ    RZ        SZ 
 
Figure 1-1 A Schematic Illustration of Injured Skeletal Muscle  
After injury, the defect (central zone (CZ)) caused by contraction of disrupted myofibers is immediately filled by a 
hematoma. Subsequent necrosis extends 1 to 2 mm along the damaged myofibers (necrosis zone (NZ) or 
regeneration zone (RZ)) from the injured site. The remaining myofibers survive the trauma (survival zone (SZ)). 
After removal of necrotic myofibers through phagocytosis, muscle regeneration occurs within RZ. Simultaneously, 
recruited fibroblasts begin to deposit ECM in the CZ. The regenerating myofibers reach out of the survived basal 
lamina of the original myofibers and penetrate the connective tissue within the CZ. However, condensed scar 
resulting from fibrosis prevents myofibers from lengthening and growing within the CZ 33. 
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 Figure 1-2 Muscle Regeneration from RZ inside Perserved Basal Membrane 
During the repair phase, macrophages enter degenerating myofibers to scavenge contractile filament bundles and 
other necrotic debris, leaving the original basal lamina (thick arrow) as a scaffold that aids in muscle regeneration. 
After removal of necrotic tissue, spindle-shaped myoblasts (thin arrow) migrate toward and stay beneath the 
preserved basal lamina, and then fuse to form small multinucleated myofibers (arrowhead).33 
 
1.1.2 TGF-β1 
Fibrosis prevents full recovery of the injured muscle 8, 40. TGF-β1 plays a major role in the 
fibrogenesis in a variety of fibrotic diseases and damaged tissues, including skeletal muscle 16-23. 
After muscle injury, the injury site contains a high level of TGF-β1 16.  Li et al. (2004) found 
that, after muscle injury, some newly regenerating myofibers express TGF-β1 protein. The TGF-
β1-positive regenerated myofibers are gradually replaced by mononucleated cells and TGF-β1-
positive scar tissue. Moreover, Li et al. showed that direct injection of TGF-β1 into skeletal 
muscle causes early TGF-β1 autocrine expression within myofibers and fibrosis 2 weeks after 
injection 16.  Antifibrotic agents that interfere with different steps of TGF-β1 signaling cascades, 
including decorin, suramin, and IFN-γ, greatly improve muscle healing after injury 29-32. Decorin 
directly interacts with TGF-β1 and prevents TGF-β1 from binding to its receptors. Suramin, an 
inhibitor of growth factor receptor activation, competitively prevents TGF-β1 from binding to 
the growth factor receptor, and by doing so inhibits the fibrotic effects of TGF-β1 31, 32. IFN-γ 
negatively regulates the TGF-β1 signaling pathway by directly inhibiting TGF-β1-induced 
phosphorylation of Smad3 and its attendant cascades, and induces the expression of inhibitory 
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Smad7. Smad7 interferes with the interaction between Smad2/3 and the TGF-β type I receptor, 
and the complex formation among phosphorylated Smad2/3 and Smad4, thereby interrupting 
Smad signaling 41. 
Not only does TGF-β1 stimulate fibrosis, it also exerts an inhibitory effect on myogenic 
differentiation of myoblasts, including the C2C12, L6, Sol 8, L6E9, C-2 and BC3H1 cell lines 42-
44. TGF-β1 also inhibits the proliferation and differentiation of muscle satellite cells45  In contrast 
with control cells, which formed multinucleated myotubes, TGF-β1-treated satellite cells 
remained mononucleated and developed distinct networks of stress fibers 45. Similarly, MSTN 
strongly inhibits proliferation and differentiation of both myoblasts and myogenic satellite cells 
46-48. 
1.1.3  Myostatin 
Myostatin (MSTN), a member of transforming growth factor-β1 (TGF-β1), is the key negative 
regulator of fetal and adult skeletal muscle growth, expressed almost exclusively in the skeletal 
muscle 49. MSTN knockout (MSTN-/-) mice are characterized by a dramatic and widespread 
increase in skeletal muscle mass 49. MSTN gene is highly conserved across different species 
arranging from zebra fish to human 49-57. Deficiency of MSTN function causes a remarkable 
increase in skeletal muscle mass from hypertrophy 50, 55, 57 or both hypertrophy and hyperplasia 
49, 51-53, 56. Recombinant MSTN and overexpressed MSTN from C2C12 myoblasts carrying 
amplified copies of a MSTN expression construct can inhibit both proliferation and 
differentiation of C2C12 myoblasts in vitro 46, 48, 58, 59. MSTN inhibits C2C12 myoblast 
proliferation by up-regulating p21, a cyclin-dependent kinase (CDK) inhibitor and decreasing the 
level and activity of Cdk2 protein. As a result, C2C12 myoblasts treated by MSTN were arrested 
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in the G0 phase of cycle46, 58.  MyoD, Myf5, MRF4, and myogenin are transcription factors of 
the basic helix-loop-helix-family of myogenic regulatory factors (MRFs).  MRFs play genetic 
hierarchy roles in the skeletal muscle development. MyoD and Myf5 are responsible for the 
determination of the myogenic lineage whereas myogenin and MRF4 are involved in the 
regulation of the process of terminal differentiation 60. MSTN decreases the expression of myoD, 
Myf5 and myogenin proteins during differentiation 48, 59.  
Like the TGF-βs, MSTN contains nine cysteine residues in the C-terminal region that is 
responsible for the activity of MSTN. After secretion, a precursor protein of MSTN undergoes 
proteolytic cleavage processing, and the resulting C-terminal regions are capable of forming a 
dimer linked by a disulfide bond 49. TGF-β1 and MSTN share some downstream steps in the 
signaling pathway. The signaling cascades of TGF-β superfamily members are classified into 
activin/TGF-β and bone morphogenetic protein (BMP)/growth and differentiation factor (GDF) 
pathways 61-63. In the former type of pathway, TGF-β, activin, and nodal-related ligands initially 
bind to type II receptors (TβRII and ActRII, respectively) and, which results in the formation of 
a complex containing 2 copies each of receptor II and receptor I (TβRI is known as activin 
receptor-like kinase (ALK): ALK5, ALK7, or ALK4). Activated type I receptors then induce the 
phosphorylation of Smad2 and/or Smad3, which further associated with Smad4. The complex of 
Smad2 and/or Smad3 and Smad4 translocates into nucleus and thereby launch the transcription 
of Smad2/Smad3-dependent target genes. In contrast, BMP/GDF-like ligands bind to BMPRII or 
ActRII/IIB. The resulting complex induces phosphorylation of Smad1, Smad5, and/or Smad8, 
which also form complex with Smad4, and thereby regulates the expression of BMP target 
genes. Recent studies have shown that, like TGF-β1 signaling, MSTN signal propagation 
requires the participation of Smad2 and Smad3 rather than the participation of Smad1, Smad5, 
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and Smad8 56, 64, 65. The binding of MSTN to ActRIIB recruits a type I receptor—either activin 
receptor 4 (ALK4 or ActRIB) or ALK5 (TβRI)—that then phosphorylates Smad2 and Smad3 
and activates a TGF-β-like signal transduction pathway56, 64, 65. MSTN signaling cascades are 
negatively regulated by the inhibitory Smad7 rather than by Smad6 64.  
Currently, research on MSTN mostly focuses on regulation of MSTN during skeletal 
muscle development. The potential role of MSTN in fibrogenesis has not been clarified and 
requires further investigation.  
1.1.4 Decorin 
Decorin (DCN), a small chondroitin-dermatan sulphate leucine-rich proteoglycan, is composed 
of a core protein and a single glycosaminoglycan chain 66, 67. Three different small proteoglycan 
with leucine-rich repeats (i.e., decorin, biglycan, and fibromodulin) are able to bind and 
inactivate TGF-β1 68. Decorin has been studied widely, primarily because it is ubiquitous in the 
ECM and has antifibrogenic properties.  
DCN is an inhibitor of TGF-β1. TGF-β1 stimulates the growth of Chinese hamster ovary 
(CHO) cells. However, the overexpression of decorin resulting from transfection of decorin 
cDNA suppresses the proliferation of transfected CHO cells compared with non-transfected 
CHO cells 66, 69. Further experiments revealed the formation of complexes between core protein 
of decorin and TGF-β1 69, 70, and then TGF-β1 was inactivated; however, the activity of TGF-β1 
dimer was restored after it was released from the complex 69. TGF-β induces synthesis of decorin 
in many cell types, which suggests that decorin may play a role in the negative feedback of TGF-
β 31, 69. Decorin has been used as an antifibrogenic agent in lung, liver, kidney, and muscle tissue 
because of its biologic binding and neutralizing of TGF-β1 28, 29, 39, 66, 71, 72. Members in our 
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research group found that decorin can improve skeletal muscle healing by promoting muscle 
regeneration and decreasing fibrosis 28, 29. In order to further investigate the mechanisms by 
which decorin exerts beneficial effects on skeletal muscle healing, whether decorin also inhibits 
MSTN was examined in this study. 
1.1.5 Myostatin Propeptide 
Analogous to TGF-β1, MSTN is synthesized as a precursor protein constituting of a signal 
sequence, an N-terminal propeptide domain, a C-terminal domain. After two proteolytic 
cleavages to remove signal sequences and propeptides, two C-terminal domains form a disulfide-
linked dimmer, which is active form of MSTN 46, 49. However, two released propeptide 
molecules are able to non-covalently bind to one MSTN dimer and inhibit its biological 
activity56, 73-75. Different research groups have shown that overexpression of MSTN propeptide 
(MPRO) in transgenic animals inhibits binding of MSTN to its receptor and consequently 
generates increased muscling 56, 57, 76. Moreover, repeated intraperitoneal injections of 
recombinant MPRO into mdx mice, an animal model of DMD, attenuate pathophysiology of 
dystrophic muscle and improve its function 77. Therefore, MPRO offers a therapeutic strategy for 
blocking MSTN in the injured and diseased muscles.  
1.1.6 Follistatin 
Follistatin (FLST), a secreted glycoprotein, initially invoked attentions due to its ability to 
antagonize activin activity in reproduction associated sites 78, 79. Later on, it was found that FLST 
is able to neutralize other several members of TGF-β family such as BMP-2, BMP-4, and BMP-
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780, GDF-1181, including MSTN 82.  Transgenic FLST overexpression mice exhibit dramatic 
increase in muscle mass, which is comparable to that seen in MSTN-/- mice 56. Systemic 
administration of FLST reduces MSTN-induced wasting 73. FLST reversed MSTN-mediated 
inhibition of muscle cell differentiation, and MSTN-inhibited expression of Pax-3 and MyoD in 
muscle cells was blocked as well. Those suggested that FLST also effectively inhibited activity 
of MSTN in vitro 82. Yeast and mammalian two-hybrid studies revealed that FLST associated 
with MSTN directly 82. The Affinity (KD) of FLST for MSTN was as high as 5.84 x 10 -10 M as 
indicated by interaction kinetics of these two molecule. FLST-MSTN coupling was very stable. 
Collectively, FLST appears to be a promising approach to improve skeletal muscle healing 
through blocking MSTN.  
1.1.7 Duchenne Muscular Dystrophy  
Duchenne muscular dystrophy (DMD) is an X-linked recessive hereditary disease resulting from 
a mutation in the dystrophin gene, which consequently produce the dysfunctional production of 
dystrophin protein83-87. Dystrophin, which resides in the sarcolemma of skeletal muscle fibers, 
works in concert with dystrophin-associated proteins (DAPs), a large oligomeric complex of 
glycoproteins, to form an assembly that connects the intracellular cytoskeleton and the 
contractile myofilament apparatus to the extracellular matrix (ECM) 84, 86, 88-91. Without 
functional dystrophin, the membranes of myofibers become susceptible to damage during 
contraction, as a result of which dystrophin deficiency muscle undergo extensive necrosis. Over 
time, DMD patients suffer repeated degeneration and functionally flawed regeneration of skeletal 
muscle, and, as the disease progresses, myogenic progenitor cells are gradually depleted.  The 
resulting extensive fibrosis and the development of regenerating myofibers with varying 
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diameters (as opposed to characteristic uniformity of normal skeletal muscle) leads an 
exacerbating cycle of skeletal muscle wasting 92.  According to statistics, approximately 1 in 
every 3,500 boys is subjected to the devastating effects of DMD and a consequently 
compromised life quality and life span 85.  
The search for therapies for DMD has primarily focused on the development of gene and 
cell therapies. The focus of gene therapy is to construct optimal vectors capable of transferring 
genes into dystrophic muscles to express functionally competent dystrophin, while cell therapy 
focuses on transplanting healthy donor cells (e.g., myoblasts) into dystrophic muscle to 
proliferate, fuse with dystrophin-deficient muscle, and generate myofibers which express 
functional dystrophin. Ultimately, cell therapy seeks to provide a growing reservoir of functional 
dystrophin and restore the structural strength and integrity of skeletal muscle 93.   
1.1.7.1 Cell Therapy 
Initial animal experiments and clinical trials have revealed that myoblast transplantation does 
result in an engraftment of dystrophin-positive myofibers; unfortunately, however, this 
engraftment is transient and causes only a minimal improvement in muscle strength 16, 94-104. 
Moreover, this restoration of dystrophin-expressing myofibers in DMD hosts did not always 
result in a functional improvement of muscle 99, 100, 103-106.  This limited success is attributed to 
several probably factors, including host immune rejection, poor cell survival, a limited 
dissemination of cells following transplantation, and an unfavorable microenviroment95, 107-112.  
While tissue engineers and biomedical scientists remain optimistic about the promises that cell 
therapies hold for treating DMD, critical limitations need to be overcome in order to successfully 
restore the long-term muscle integrity and function of these patients.  
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1.1.7.2 Regeneration Capacity of Muscle-Derived Stem Cells 
An alternative type of cell that appears to be better-suited for the cell-based therapy of 
musculoskeletal diseases such as DMD is the muscle-derived stem cells (MDSC).  Compared to 
myoblasts, MDSCs are less immunogenic 113, which likely contributed to enhances engraftment 
following transplantation into immunocompetent hosts; in one study, MDSCs injected into 
dystrophic skeletal muscle generated ten times more dystrophin-positive myofibers compared to 
myoblasts 113. MDSCs are also significantly more versatile compared to myoblasts; several 
studies indicate that MDSCs are multipotent, as they can differentiate toward myogenic, 
hematopoietic, osteogenic, chondrogenic, adipogenic, neural, and endothelial lineages 113-119. 
Finally, their proliferative capacity is ideal for permitting tissue engineers to obtain adequate 
numbers of undifferentiated stem cells for cell-based therapy. Further studies are underway to 
determine the efficacy of these cells for such therapies.  
While there have been exciting advancements in the treatment of DMD with stem cell 
therapy, this therapy may best be served in combination with gene therapy. For instance, ex vivo 
gene therapy provides a feasible alternative in which  autologous cells are isolated from healthy 
tissue, genetically modified to secrete a protein of interest (e.g., myostatin propetide), expanded 
in vitro, and re-implanted either systemically or locally 120  The protein carried by donor cell may 
favor donor cells to form more dystrophin positive myofibers in host muscle than non-modified 
cells without genetic modification. While this approach may provide superior cell transplantation 
and long-term results, further studies are ongoing 121. 
1.1.7.3 Benefit of blocking the myostatin signal in myoblast transplantation 
Since MSTN negatively regulates proliferation and differentiation of muscle cells, suppression of 
MSTN signaling pathway might be an effective way to boost the efficiency of cell 
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transplantation in the skeletal muscle. Tremblay’s group generated a transgenic domain negative 
activin receptor IIB (dnActRIIB) mouse that acquired double-muscling phenotype due to 
dnActRIIB’s inactivating MSTN. They reported that transplantation of myoblasts isolated from 
dnActRIIB mice into mdx mice led to improved success of cell transplantion, indicated by 
significantly larger dystrophin-positive engraftment resulted from dnActRIIB myoblasts than 
normal myoblasts122. In the current study, we took the advantage of WT, MSTN-/-, and FLST 
overexpression (FLST/OE) mice. Using modified preplate technique, we isolated up to 7 
populations of muscle progenitor cells (MPCs) from each type of WT, MSTN-/-, and FLST/OE 
mice. And then, whether blockade of MSTN signal in donor cells might have beneficial effect on 
MPC transplantation was extensively examined.   
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2.0  PROJECT OBJECTIVES 
2.1 OBJECTIVE# 1: TO DETERMINE POTENTIAL RELATIONSHIP BETWEEN 
TGF-β1, MSTN AND DECORIN IN INJURED SKELETAL MUSCLE 
MSTN caught our interests due to the dual roles that it plays in the skeletal muscle. First, MSTN 
is known as the most potent inhibitor of the development and growth of the skeletal muscle 49. 
Second, MSTN also showed it potential in inhibiting fibrosis in the skeletal muscle. Mdx mice, 
with MSTN deficiency, (MSTN-/-/mdx) not only show less muscle damage, better regeneration, 
but also less collagenous tissue deposition than their mdx counterparts 123. However, since 
skeletal muscle regeneration and fibrosis compete with each other. It is unclear whether the 
decreased fibrosis in MSTN-/-/mdx mice is secondary to enhanced regeneration, or whether 
MSTN may directly promote fibrosis. Therefore, the efforts to clarify the role of MSTN in the 
skeletal muscle fibrosis are warranted. Although it is widely accepted that TGF-β1 is a putative 
growth factor in triggering fibrotic cascades in injured and diseased skeletal muscles; however, 
in order to develop effective biological approaches to the injured skeletal muscle,  it is crucial to 
understand the mechanisms underlying fibrosis, especially to identify other potential candidates 
that participates in triggering fibrosis. We hypothesized that MSTN enhances the formation of 
fibrosis in the injured skeletal muscle. If this hypothesis is proven, we would further 
hypothesized that neither TGF-β1 nor MSTN induces fibrosis alone in the skeletal muscle, and 
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instead these two molecules may synergistically activate fibrotic cascades, regarding to the 
similarities shared by TGF-β1 and MSTN.  Finally, among different antifibrotic agents that we 
have demonstrated to improve skeletal muscle healing, decorin is superior to others, because it is 
able to directly upregulate regeneration by stimulate myogenesis, and downregulate fibrosis by 
blocking TGF-β1. We were intrested in whether decorin inhibits MSTN as it did TGF-β1. 
Therefore, that was also investigated in this study. 
2.2 OBJECTIVE #2: TO INVESTIGATE HOW SKELETAL MUSCLE HEALING 
CAN BE IMPROVED BY BLOCKING MSTN SIGNALING USING MSTN-/- MICE  
AND MSTN PROPEPTIDE (MPRO), AN INHIBITOR OF MSTN 
In the objective#1, we observed improved skeletal muscle healing in MSTN-/- mice revealed by 
the enhanced muscle regeneration and reduced fibrosis when compared to WT mice. However, 
how blocking MSTN signaling benefits skeletal muscle healing remains unclear. Based on 
information in the literature, the development of fibrosis appears to be negatively related to the 
extent of blood supply 124. Our preliminary results showed that improved muscle healing in 
MSTN-/- mice coincided with higher vascularity than seen in WT mice. Transgenic mice have 
been very useful tool and widely used by researcher, however, problems rise in efforts to 
translate promising results collected from transgenic animals to clinic. To circumvent those 
obstacles, we therefore used adeno-associated virus (AAV) to deliver MSTN propeptide cDNA 
into gastrocnemius muscle of WT mice to restrict expression of exogenous MPRO within the 
certain skeletal muscle. With this model, we investigated whether inhibition of MSTN by MPRO 
reduces fibrosis, promotes neovascularization and muscle regeneration in injured skeletal 
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muscle. Moreover, we also examined whether with the removal of MSTN, muscle progenitor 
cells (MPCs) isolated from MSTN-/- skeletal muscle possesses stronger muscle regeneration 
capacity than MPCs obtained from WT skeletal muscle. Our laboratory has developed a 
modified preplate technique 113, 125, with which, we are able to isolate muscle progenitor cells 
from mice 113, 125-127, pig, and human (unpublished data). Blocking MSTN signaling with 
different inhibitors (e.g., MPRO, FLST) has been shown to improve muscle regeneration and 
reduce fibrosis in mdx mice. We further explored whether inhibiting MSTN in the host 
mdx/SCID mice by AAV-MPRO enhances regeneration capacity of transplanted muscle 
progenitor cells. 
2.3 OBJECTIVE #3: TO EVALUATE THERAPEUTIC EFFECT OF FLST ON 
INJURED SKELETAL MUSCLE 
Furthermore, we developed biological approaches to block skeletal muscle fibrosis with the use 
of follistatin. FLST, a secreted protein, is able to bind and antagonize the action of MSTN. We 
investigated whether transgenic FLST overexpression (FLST/OE) mice develop less fibrosis and 
more muscle regeneration in the injured skeletal muscle than do WT mice. If so, we would 
isolate MPCs from skeletal muscles of WT mice and transgenic FLST/OE, mice. When these 
resulting muscle progenitor cells (MPCs) are transplanted in dystrophic muscle in mdx mice, 
they can fuse with each other or into host myofibers to regenerate dystrophin-positive 
engraftment consisting of myofibers formed from donor cells. The number of dystrophin-postive 
myofibers is an index to indicate how efficiently MPCs participate in skeletal muscle 
regeneration125, 128. Using these cell populations, we would compare the influence of gain 
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function of FLST genes on muscle cell’s ability to regenerate skeletal muscle, when they are 
transplanted into dystrophic muscle.      
2.4 SIGNIFICANCE 
The overall goal of this project was to further establish the role of MSTN in the skeletal muscle 
fibrosis, explore whether TGF-β1 and MSTN synergistically act together to induce fibrosis, and 
how inhibition of MSTN results in improved muscle healing. Those findings help us to clarify 
the mechanisms of fibrosis in injured skeletal muscle, which eventually lead to an optimal 
approach to treat injured muscle. Moreover, we also would like to determine whether MPRO or 
FLST, antagonists of MSTN, can effectively block the activity of MSTN in vivo, thus enhance 
muscle healing. Positive results will provide us an alternative avenue to improve muscle healing 
through targeting MSTN.  
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3.0  RELATIONSHIPS BETWEEM TGF-β1, MYOSTATIN, AND DECORIN: 
IMPLICATIONS FOR SKELETAL MUSCLE FIBROSIS 
3.1 INTRODUCTION 
MSTN, a member of the TGF-β superfamily, was initially identified as a negative regulator of 
the growth and development of skeletal muscle 49. Recent studies have shown that MSTN, may 
also be involved in fibrosis formation within the skeletal muscle 123. Mdx mice (an animal model 
for Duchenne muscular dystrophy) in which expression of the MSTN gene has been ablated 
(MSTN-/-/mdx) not only showed better skeletal muscle regeneration, but also exhibited 
decreased fibrosis when compared to mdx mice (MSTN+/+/mdx) 123. These results strongly 
suggest that MSTN plays an important role in muscle fibrosis; however, a direct link between 
MSTN and fibrosis has yet to be identified. To investigate this possibility, we evaluated the 
effect of MSTN on fibroblasts, cells responsible for the synthesis of ECM components, and the 
fibrosis formation in injured skeletal muscle. Due to the fact that TGF-β1 plays a major role in 
the formation of fibrosis, we hypothesized that a relationship between TGF-β1 and MSTN exists. 
Because decorin (DCN) has been shown to strongly inhibit fibrosis formation in various tissues 
via blocking of TGF-β1 activity 28, 29 39, 72, 129, 130, we investigated the potential for DCN to inhibit 
the activity of MSTN as it does for TGF-β1. Our findings demonstrated that MSTN is involved 
with the formation of fibrosis and interacts with TGF-β1, and that DCN has the ability to 
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counteract the action of MSTN. These results contribute to a better understanding of the 
mechanism of skeletal muscle healing, and indicate that MSTN represents a potential 
pharmacological target for anti-fibrogenic therapy. 
3.2 METHODS 
3.2.1 Isolation of Fibroblasts from Skeletal Muscle  
The preplate technique was used to isolate fibroblasts from skeletal muscle 113. Collagen-coated 
flasks were used in the isolation process since fibroblasts adhere more readily to collagen than 
myoblasts. After 6-week-old female C57BL/6J mice were sacrificed, their gastrocnemius 
muscles (GMs) were removed and minced into coarse slurry. The muscle slurry was digested 
with 0.2% collagenase (type XI) for 1 h, followed by a dispase digestion (grade II, 240 mL) for 
30 minutes, followed by a 0.1% trypsin digestion for a final 30 minutes at 37ºC. The extracted 
muscle cells were resuspended in proliferation medium (PM)   consisting of Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA), 10% horse serum (HS; 
Invitrogen, Carlsbad, CA), 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), 1% 
penicillin/streptomycin (P/S; Invitrogen, Carlsbad, CA), and 0.5% chicken embryo extract (CEE; 
Accurate Chemical & Scientific Corporation, Westbury, NY) and plated onto collagen-coated 
flasks. A population of preplated cells (PP1), consisting of mostly fibroblasts that attached within 
the first 2 hours, was collected and used, in these experiments, as skeletal muscle derived 
fibroblasts.  
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3.2.2 Cell Culture  
The NIH3T3 fibroblast cell line and the C2C12 myoblast cell line were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA). The cell lines or isolated PP1 
fibroblasts were maintained in PM consisting of DMEM, 10% FBS, and 1% P/S until further 
needed. PP1 fibroblasts were plated onto collagen coated 96-well plates for cell proliferation 
analysis and onto 6-well plates for the evaluation of α-smooth muscle actin (α-SMA), fibronectin 
(FN), collagen (typeIα1, IIα2, and IIIα1), and MSTN expression. Following an overnight 
incubation, PM was replaced with serum-free medium supplemented with a serum replacement 
(Sigma, St. Louis, MO) consisting of heat-treated bovine serum albumin, heat-treated bovine 
transferrin, and bovine insulin. This serum replacement does not contain growth factors, steroid 
hormones, glucocorticoids, or cell adhesion factors. We further supplemented this media with 
varying concentrations of recombinant human MSTN (Leinco Technologies, Inc. St. Louis, MO) 
for proliferation assays (0, 100, 500, or 1000 ng/mL) and for western blot analysis (0, 100, or 
500 ng/mL). After incubation for 48 h, an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) cell proliferation assay kit (Roche Diagnostics, Germany) was 
used to measure cell proliferation (n=6) following the instructions from the manufacturer. 
Western blot analysis was used to examine α-SMA, fibronection, and MSTN expression. Some 
of the above procedures were repeated using NIH3T3 fibroblasts to confirm the effect of MSTN 
on fibroblasts. C2C12 myoblasts, a widely used myogenic cell line 46, 48, 131, were used to 
examine whether DCN neutralized the inhibitory effect of MSTN on cell differentiation. We 
seeded C2C12 myoblasts in 12-well plates in PM at a density of 10,000 cells/well. Following an 
overnight incubation, PM was replaced with fresh differentiation medium (DM) containing 
DMEM, 2% HS, and 1% P/S. We maintained a total of four sets of cultured cells. The control set 
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received only DM while the other sets received DCN alone, MSTN alone, or 1 µg/mL of MSTN 
combined with 0-50 µg/mL DCN (n = 3). Cells were cultured for 5 more days during which DM, 
MSTN, and DCN were changed every other day. Following a similar procedure, we examined 
whether recombinant follistatin (FLST) protein stimulated myogenic differentiation of C2C12 
myoblasts (n = 3), and whether soluble TGF-β1 receptor type II (100 ng/mL, and 1000 ng/mL) 
(TβRII) (R&D Systems, Inc. Minneapolis, MN) was able to attenuate MSTN-inhibited myoblast 
differentiation (n = 3).  
3.2.3 Western Blot Analysis  
After culturing, the cells were lysed with T-PER® Tissue Protein Extraction Reagent with the 
addition of protease inhibitors (Pierce, Rockford, IL). Equal amounts of cellular protein were 
loaded into each well and separated by 10% sodium dodecyl sulfatepolyacrylamide gel 
electrophoresis (SDS-PAGE). Nitrocelluose membrane blotting was performed under standard 
conditions, which was followed by a 2h blocking in 0.05% Tween-20 phophate buffered saline 
containing 5% nonfat milk at room temperature. The following primary antibodies were used for 
immunoblotting: mouse anti-β-actin IgG (1:8,000) (Sigma, St Louis, MO), mouse anti-GAPDH 
IgG (1:5,000) (Abcam Inc, Cambridge, MA), rabbit anti-MSTN IgG (1:3,000) (Chemicon, 
Temecula, CA), mouse anti-α-SMA IgG (1:1,000) (Sigma, St Louis, MO), mouse anti-
fibronectin (FN) IgG (1:3,000), and rat anti-TGF-β1 IgG (1:1000) (BD PharMingen, San Jose, 
CA).  
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3.2.4 Quantitative RT-RCR 
Quantitative RT-PCR (Q-RT-PCR) was used to examine the mRNA expression levels of 
procollagen (type Iα1, Iα2, and IIIα1) in PP1 fibroblasts treated with MSTN (100, 200, and 500 
ng/mL) for 12, 24, and 48h. The mRNA was extracted using an Rneasy Plus kit (Qiagen Inc. 
Valencia CA). The cDNA templates for Q-RT-PCR were synthesized using a RETROscript® kit 
(Ambion Inc., Austin, TX). Q-RT-PCR was carried out in an ABI Prism 7000 Sequence Detector 
(Applied Biosystems, Foster City, CA) with SYBR Green PCR Master Mix Reagent (Applied 
Biosystems, Foster City, CA) as a detector. All target gene expressions were normalized to 18s 
rRNA levels. The primer pair of procollagen IIIα1 was from a previous study 132. The primer 
pairs are displayed in Table 1. 
 
Table 1. The Sequences of Primer Pairs for Q-RT-PCR 
Gene Name                                                     Primer pairs 
                                                       (S: sense primer, A: Anti-sense primer)            PCR products (bp) 
Procollagen type I alpha 1             S: 5'-GAAGAACTGGACTGTCCCAAC-3'                   103 
(BC050014)                                   A: 5'-CCTCGACTCCTACATCTTCTG-3' 
Procollagen type I alpha 2             S: 5'-TCTGGTAAAGAAGGCCCTGTG-3'                    106 
(AK075707)                                  A: 5'-GTCCAGGGAATCCGATGTTG-3' 
Procollagen type III alpha 1          S: 5'-AGGCTGAAGGAAACAGCAAA-3'(45)               116 
(AK041115)                                  A: 5'-TAGTCTCATTGCCTTGCGTG-3' 
TGF-beta 1                                    S: 5'-CTAATGGTGGACCGCAACAAC-3'                     99 
(BC 013738)                                 A: 5'-CACTGCTTCCCGAATGTCTGA-3' 
18s rRNA                                                     Prprietary of ABI                                         N/A                 
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3.2.5 Enzyme-Linked Immunosorbent Assay   
Enzyme linked immunosorbent assay (ELISA) was performed to determine whether recombinant 
MSTN protein stimulated TGF-β1 secretion in C2C12 myoblasts. C2C12 myoblasts were plated 
into a 48-well plate and exposed to a range of MSTN concentrations from 0 to 500 ng/ml. Fresh 
recombinant MSTN protein was added every two days. Cell supernatants were collected at 2 and 
4 days (n = 5). These supernatants were centrifuged to remove cell debris and stored at -80ºC 
until the ELISA was performed. The Mouse/Rat/Porcine TGF-β1 immunoassay kit (R&D 
Systems, Inc., Minneapolis, MN) was used to quantitatively measure the secreted TGF-β1 levels 
in cell culture supernatants, according to the manufacturer’s protocol. 
3.2.6 Immunocytochemistry  
 In order to monitor the differentiation capacity of the myogenic cells, they were fixed in cold 
methanol for 2 minutes after induction of differentiation in 12-well plates. Following a phosphate 
buffered saline (PBS) wash, the cells were blocked with 10% HS (Vector Laboratories, Inc., 
Burlingame, CA) for 30 minutes, and then incubated with an anti-myosin heavy chain (MyHC) 
antibody (Sigma, St Louis, MO) in 2% HS overnight. A negative control was performed by 
omitting the primary antibody. The next day, after several PBS rinses, the cells were incubated 
with the secondary antibody goat anti mouse IgG conjugated with Cy3 (Sigma, St Louis, MO) 
for 1 hour. Hoechst 33258 dye was used in each experiment to stain cell nuclei. Fusion index 
(ratio of nuclei in myotubes to all nuclei) was calculated (%) to evaluate myogenic 
differentiation. 
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3.2.7 Animal Model  
All experimental animal protocols were approved by the Animal Research and Care Committee 
in the Children’s Hospital of Pittsburgh (protocols 15-3 & 17-05). C57BL/6 wild-type (WT) 
(Jackson Laboratories, Bar Harbor, ME) and MSTN-/- mice (7 to 8 weeks of age) were used in 
this study. All MSTN-/- mice used were offspring of MSTN-/- homozygotes, and PCR was used 
to confirm the genotype of all MSTN-/- mice. The RT-PCR test was randomly used to confirm 
the lack of MSTN gene transcription in MSTN-/- mice throughout the experiments. The skeletal 
muscle mass of MSTN-/- mice and WT mice were also compared to confirm the desired 
phenotype. The mice were anesthetized with isofluorane controlled under an IMPAC6 anesthetic 
delivery machine (VetEquip, Pleasanton, CA). Both GMs of each mouse were laterally lacerated 
to create an injury model as previously described 29, 30, 32. A surgical blade (no. 11) was used to 
make a lateral laceration through 50% of the muscle width and 100% of the muscle thickness in 
the area of the GM with the largest diameter. We harvested the mouse GMs at 2 and 4 weeks 
post-surgery. There were 6 to 8 mice (12 to16 GMs) in the WT and MSTN-/- mouse groups for 
both time-points. The muscles were isolated, removed, and snap-frozen in 2-methylbutane 
precooled in liquid nitrogen. After Masson’s trichrome staining (IMEB Inc., Chicago, IL), 
Northern Eclipse software (Empix Imaging, Inc., Cheektawaga, NY) was used to measure areas 
of fibrotic tissue in the injured sites. In each sample, three representative non-adjacent sections 
were chosen. The ratio of the fibrotic area to the cross sectional area was used to estimate the 
extent of fibrosis formation. To determine the skeletal muscle’s regeneration efficiency, minor 
axis diameters (the smallest diameter) of regenerating muscle fibers were measured using 
Northern Eclipse software on cross-sections of GMs. The diameters of over 350 consecutively 
centronucleated myofibers were measured in each GM.  
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3.2.8 Immunohistochemistry  
Frozen GMs were sectioned at 10 μM thickness and immunohistochemical analysis was 
performed to detect DCN expression. Tissue sections were fixed in 4% formalin for 5 minutes 
followed by two 10-minute washes with PBS. The sections were then blocked with 10% HS for 
1 hour. The rabbit anti-DCN IgG (LF-113, National Institute of Dental Research, Bethesda, MD) 
primary antibody was diluted 2:100 in 2% HS and incubated with sections overnight at 4ºC ) to 
stain tissue sections of WT and MSTN-/- GMs 2 weeks after laceration. The following day, the 
sections were washed three times with PBS and then incubated with the secondary antibody, goat 
anti-rabbit IgG conjugated with Cy3 (Sigma, St. Louis, MO).   
3.2.9 Statistical Analysis  
All of the results from this study are expressed as the mean ± standard deviation (SD). The 
differences between means were considered statistically significant if Ρ <0.05. The Student’s t-
test was used to compare the difference in skeletal muscle regeneration, and fibrosis formation 
between MSTN-/- and WT mice, and the myogenic differentiation capacity between MSTN-/- 
and WT LTP cells. All other data were analyzed by analysis of variance (ANOVA) followed by 
post hoc Tukey's multiple comparison test. Error bars on the figures represent the SD, * 
represents Ρ < 0.05, and ** represents Ρ < 0.01. 
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3.3 RESULTS 
3.3.1 Effects of MSTN on Fibroblasts  
MTT proliferation tests showed that, after 48 h of incubation, MSTN significantly stimulated the 
proliferation of PP1 and NIH3T3 fibroblasts in a dose-dependent manner (Figure 3-1A). Alpha-
smooth muscle actin (α-SMA), the actin isoform originally found in contractile vascular smooth 
muscle cells, has been the most reliable marker of myofibroblasts to date 24. Western blot 
analysis indicated that MSTN (100 and 200 ng/mL) increased α-SMA expression in PP1 and 
NIH3T3 fibroblasts (Figure 3-1B). Q-RT-PCR revealed that MSTN stimulated procollagen 
(type Iα1, Iα2, and IIIα1) mRNA expression at 48 h (Figure 3-1C). Additionally, MSTN 
stimulated the expression of fibronectin (FN) protein, a component of extracellular matrix 
(ECM), in PP1 fibroblasts (Figure 3-1 D).  
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Figure 3-1 MSTN Stimulated Proliferation and ECM Production of Fibroblasts 
A, both muscle-derived fibroblasts (PP1) and NIH3T3 fibroblasts were cultured with MSTN, varying in 
concentration from 0 to 1000 ng/ml for 48 h. Cell proliferation was determined by MTT assay. These results are 
presented as absorbance values (n = 6) of purple formazan crystal at 570 nm, which directly correlates to the number 
of living cells. Fibroblasts were cultured in DM for 2 days with the addition of various concentrations of MSTN. 
Expressions of different proteins were analyzed by Western blot. B, the expression of α-SMA in PP1 fibroblasts or 
NIH3T3 fibroblast is shown. C, Q-RT-PCR analysis of procollagen (types Iα1, Iα2, and IIIα1) mRNAexpression in 
PP1 fibroblasts treated with MSTN. Results are presented as the ratio against the gene expression in the control. D, 
expression of FN in PP1 fibroblasts after MSTN treatment (*, P < 0.05; **, P <0.01). 
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3.3.2 Reduced Fibrosis and Enhanced Skeletal Muscle Regeneration in MSTN-/- Mice             
3.3.2.1 Reduced fibrosis in injured MSTN-/- mice 
At 2 weeks following injury, we observed extensive deposition of collagenous tissue in the WT 
and MSTN-/- mice (data not shown). After 4 weeks, the deepest area of the injured site was 
filled with regenerating myofibers of large diameter, and the fibrotic region was limited to the 
superficial zone of the laceration site (Figure 3-2A). We observed fewer fibrotic connective 
tissue deposits between regenerating myofibers in the injured muscle of MSTN-/- mice 
compared to the prominent scar region in the injured WT mouse muscle (Figure 3-2A). 
Quantification of fibrotic tissue (i.e., the ratio of the fibrotic area to the cross-sectional area) 
revealed that there was a significantly smaller fibrous area in MSTN-/- skeletal muscle as 
compared to WT skeletal muscle at 2 weeks (11.5 ± 3.5% vs. 15.3 ± 3.1%; Ρ < 0.01) and at 4 
weeks (2.1 ± 0.4 vs. 6.3 ± 2.1; Ρ < 0.01) after injury (Figure 3-2B).  
3.3.2.2 Improved muscle regeneration in injured MSTN-/- mice 
We used the minor axis diameter (smallest diameter) of centro-nucleated regenerating myofibers 
to evaluate skeletal muscle regeneration after laceration injury. At 2 weeks after GM laceration, 
regenerating myofibers were relatively small (data not shown). At 4 weeks, some large, mature 
myofibers could be observed among the small, centronucleated, regenerating myofibers (Figure 
3-2C). Quantification showed that MSTN-/- regenerating myofibers had diameters 38.8% larger 
than WT myofibers (36.1± 2.5 μm vs. 26.0 ± 2.2 μm; Ρ < 0.01) at 2 weeks after laceration, and 
the mean diameter of regenerating myofibers in MSTN-/- mice remained 21.1% larger than the 
mean diameter of regenerating myofibers in the WT mice (37.7 ± 2.7 μm vs. 31.1 ± 1.8 μm; Ρ 
<0.01) 4 weeks after injury (Figure 3-2D). 
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 Figure 3-2 Inhibition of MSTN Facilitates Skeletal Muscle Healing after Injury 
A, sections from injured WT and MSTN-/- GMs were stained with Masson’s trichrome-staining protocol 4 weeks 
after laceration to determine fibrotic tissue levels. As a result, collagenous tissue is stained blue. B, quantification of 
fibrotic tissue of WT versus MSTN-/- GMs 2 and 4 weeks after laceration. C, myofibers in WT and MSTN-/- GMs 
were visualized by hematoxylin and eosin staining 4 weeks after laceration. Regenerating myofibers were 
distinguished by their centralized nuclei. D, quantification of the diameters of regenerating myofibers. E, the 
distribution of regenerating myofiber diameters at 4 weeks after laceration injury. F, increased DCN 
immunostaining in injured skeletal muscle of MSTN-/- mice compared with WT mice 2 weeks after laceration. 
DCN (red) is detected in the ECM between myofibers. (Magnifications: in C and F, x200; in A, x100; *, P< 0.05; 
**, P < 0.01.) 
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The mean diameter of regenerating myofibers in MSTN-/- mice was significantly higher than the 
mean diameter of the regenerating myofibers in WT mice (Figure 3-2D). The distribution of the 
regenerating myofiber diameters showed that there was an increase in the percentage of larger 
regenerating myofibers in MSTN-/- mice compared to WT mice (e.g., approximately 7.38% of 
regenerating myofiber diameters in MSTN-/- mice fell into a range of 50 to 55 μm vs. 1.92% of 
those in WT mice (Figure 3-2E). 
3.3.2.3 Elevated DCN expression in injured MSTN-/- mice 
To investigate the underlying mechanism for improved muscle healing in MSTN-/- mice, we 
examined the expression of DCN, a molecule that has been shown to decrease fibrosis and 
enhance muscle regeneration in injured MSTN-/- skeletal muscle 16, 29. Immunohistochemical 
staining revealed that there was more abundant DCN expression in the regenerating skeletal 
muscle of MSTN-/- mice than that of WT mice 2 weeks after injury (Figure 3-2F). This higher 
level of DCN expression may be related to the increased regeneration and decreased fibrosis 
shown in the injured muscle of MSTN-/- mice. 
3.3.3 Relationship between TGF- β1 and MSTN  
Western blot analysis showed that the levels of MSTN in C2C12 myoblasts treated with different 
concentrations of TGF-β1 were elevated in a dose dependent manner when compared to non-
treated controls, suggesting that TGF-β1 stimulates MSTN expression in C2C12 myoblasts 
(Figure 3-3A). After incubation with increasing concentrations of recombinant MSTN protein, 
MSTN was shown to stimulate TGF-β1 expression in C2C12 myoblasts especially with the 
highest dose at 4 days poststimulation (Figure 3-3B). Furthermore, ELISA showed that MSTN 
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significantly increased TGF-β1 secretion by C2C12 myoblasts in a dosedependent manner at 2 
and 4 days. After 4 days of stimulation with MSTN (500 ng/mL), C2C12 myoblasts secreted 
approximately twofold more TGF-β1 as compared to control cells (Figure 3-3C). Q RT-PCR 
revealed that MSTN (100, 200, and 500 ng/ml) also increased TGF-β1 mRNA expression 48 h 
post-stimulation (Figure 3-3D). PP1 fibroblasts did not express detectable MSTN protein. 
However, after treatment with MSTN (100 and 200 ng/ml) for 48 h, PP1 fibroblasts began to 
express MSTN as indicated by western blot analysis (Figure 3-3E). MSTN also stimulated 
MSTN expression in C2C12 myoblasts (Figure 3-3E). MSTN-induced MSTN autocrine 
expression in PP1 fibroblasts is reduced by soluble TGF-β1 receptor type II (TβRII) which 
blocks the TGF-β1 signaling pathway (Figure 3-3F). Moreover, our results indicated that soluble 
TβRII was also able to restore MSTN inhibited C2C12 myoblast differentiation (Figure 3-3G). 
We also examined whether exogenous TGF-β1 recombinant protein was able to stimulate 
autocrine expression of TGF-β1 in MSTN-/- muscle cells as it does in C2C12 myoblasts 16. We 
observed that exogenous TGF-β1 could induce its autocrine expression in WT primary myoblasts 
but not on primary MSTN-/- myoblasts (Figure 3-3H). 
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Figure 3-3 Interaction between TGF-β1 and MSTN in vitro  
A, Western blot analysis of MSTN expression in C2C12 myoblasts treated with different concentrations of TGF-β1 
ranging from 0 to 5.0 ng/ml for 48 h. B, C2C12 myoblasts were treated with different concentrations of MSTN in 
DM. Cell lysates were collected at 2 and 4 days to examine TGF-β1 expression by Western blot; C, while the 
conditioned medium was collected at the same time points, the levels of TGF-β1 in the medium were also analyzed 
by ELISA. D, Q-RT-PCR for TGF-β1 after MSTN treatment (100, 200, and 500 ng/ml) in PP1 fibroblasts. E, the 
level of MSTN expression in PP1 fibroblasts and C2C12 myoblasts treated with MSTN recombinant protein. F, 
Western blots were used to determine MSTN expression level in PP1 fibroblasts after cells were treated with 
eitherMSTNor bothMSTNand soluble TβRII for 48 h. G, C2C12 myoblasts were cultured in DM with different 
treatments, TGF-β1, MSTN, TGF-β1 and TβRII, or MSTN and TβRII, for 4 days. Fusion indexes were used to 
access impacts of treatments on C2C12 myoblast differentiation. H, myoblasts isolated from WT, and MSTN-/- 
GMs were grown for 48 h under stimulation by TGF-β1. Western blot analysis was used to detect TGF-β1 
expression in WT and MSTN -/- cells (*, P < 0.05; **, P <0.01). 
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 Figure 3-4 DCN Attenuated the Effects of MSTN on Fibroblasts and Myoblasts 
A, PP1 fibroblasts were treated for 48 h with 100 ng/ml MSTN or combinations of MSTN and DCN. Non-treated 
cell cultures were used as a control. MTT assay was performed to assess cell proliferation. B, after incubation of 
PP1 fibroblasts with MSTN, or a combination of MSTN and DCN, Western blot analysis was performed to 
determine whether DCN reduced the autocrine expression of MSTN in PP1 fibroblasts stimulated with MSTN. C, 
C2C12 myoblasts were cultured without treatment, with 1µg/ml MSTN alone, or co-incubated with 1µg/ml MSTN 
and different concentrations of DCN for 5 days. Myotubes were monitored by anti-skeletal myosin heavy chain 
immunostaining; nuclei were stained by Hoechst 33258 (magnification, x100). D, fusion indexes were determined to 
estimate the differentiation capacity of C2C12 myoblasts in response to different treatments. 
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3.3.4 DCN Counteracts the Effect of MSTN  
 
 
Figure 3-5 DCN Stimulated Expression of FLST and FLST Promoted Myogenic Differentiation of Myoblasts 
A, DCN increased the expression of FLST in C2C12 myoblasts 48 and 72 h after treatment. B, immunofluorescence 
analysis of myotubes. C2C12 myoblasts were maintained in DM for 5 days in the presence of different 
concentrations of FLST. Myotubes were double-labeled with an antibody recognizing skeletal myosin heavy chain 
and with the fluorescent nuclear dye Hoechst 33258 (magnification, x100). C, fusion indexes were calculated to 
evaluate the degree of C2C12 myoblast differentiation upon FLST stimulation. 
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As previously shown in Figure 3-1A, 0.1 µg/ml MSTN significantly stimulated PP1 fibroblast 
proliferation. This dosage was selected to examine whether DCN could reduce the proliferative 
influence of MSTN on PP1 fibroblasts. After PP1 fibroblasts were incubated with MSTN and 
exposed to varying concentrations of DCN for 48 h, MTT assay revealed that the addition of 
DCN significantly repressed MSTN’s stimulatory effect on PP1 proliferation in a dose-
dependent manner as expected (Figure 3-4A). These findings are comparable to a previous 
report showing that DCN blocked the stimulatory effect of TGF-β1 on PP1 fibroblasts 29. Our 
earlier results indicated that MSTN induced its own expression in an autocrine manner in PP1 
fibroblasts (Figure 3-3E). Therefore, we examined the ability of DCN to block the MSTN 
autocrine expression in PP1 fibroblasts. As previously shown, PP1 fibroblasts, which were not 
treated with MSTN, failed to express detectable MSTN protein, while PP1 fibroblasts treated 
with MSTN showed a high level of MSTN expression in comparison to the control (Figure 3-3E, 
3-4B). However, DCN decreased MSTN autocrine expression by PP1 fibroblasts in a dose-
dependent manner (Figure 3-4B). Our previous experiments showed that 1 µg/mL MSTN almost 
completely inhibited myoblast differentiation (data not shown). Therefore, we chose this dose to 
assess whether DCN treatment could reverse MSTN-inhibited myogenic differentiation in 
C2C12 cells. Except for the control cells, the cultures were treated with DCN alone, MSTN 
alone, or 1 µg/ml MSTN combined with increasing concentrations of DCN (0-50 µg/ml). 
Following a 5-day incubation, DCN treated-groups (data not shown) and controls showed 
widespread myosin heavy chain (MyHC)-positive myotubes, whereas cells treated with MSTN 
alone contained only a few myotubes (Figure 3-4C). The addition of DCN reversed the 
inhibition of MSTN on myogenic differentiation, as indicated by the increase in the number and 
size of myotubes in comparison to the MSTN-treated group (Figure 3-4C). Measurements 
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showed that DCN treatment promoted C2C12 myoblast differentiation by significantly 
increasing fusion indexes in a dose-dependent manner (Figure 3-4D), suggesting that DCN 
attenuated the inhibitory effect of MSTN and thereby, stimulated myoblast fusion. 
3.3.5 Inhibitory Effects of DCN on MSTN may be Mediated by FLST 
To further explore whether DCN regulated MSTN activity via an intermediate molecule, we 
investigated the effect of DCN on the expression of follistatin (FLST), which is able to bind to 
MSTN and suppress its activity 82. We found an up-regulation of FLST expression by C2C12 
myoblasts 48 and 72 h after addition of 10 µg/ml DCN (Figure 3-5A). Our results also revealed 
the ability of FLST to stimulate myogenic differentiation, which was demonstrated by the 
presence of larger myotubes containing more nuclei in comparison to the control group (Figure 
3-5B). In a dose-dependent manner, FLST treatment led to a significant increase in fusion index 
(Figure 3-5C) compared to the control group, suggesting that FLST promotes myogenic 
differentiation and accelerates the maturation of myotubes. 
3.4 DISCUSSION 
MSTN has been drawing more and more attention due to mounting evidence indicating that 
inhibition of MSTN significantly improves skeletal muscle diseases such as muscle dystrophy. 
But, the role of MSTN in injured skeletal muscle and its relationships with other molecules such 
as TGF-β1 and DCN (important key factors in muscle healing) remain unknown.  
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3.4.1 Fibrotic Roles of MSTN in Vitro and in Vivo 
Recent studies reported by Yamanouchi et al. highlight the expression of MSTN in fibroblasts in 
injured skeletal muscle 133, suggesting that fibroblasts may be a source of MSTN. Previously, we 
have shown that TGF-β1 significantly promotes proliferation of PP1 fibroblasts 29. Here, our in 
vitro study shows that MSTN activates fibroblasts by stimulating fibroblast proliferation and 
inducing their expression of α-SMA analogous to that of TGF-β1 in an autocrine manner. Like 
TGF-β1 134, MSTN may transiently attract fibroblasts into an injury site, further inducing them to 
express MSTN in an autocrine fashion; they then differentiate into myofibroblasts, thereby 
accelerating the deposition of the ECM. Researchers widely believe that prolonged presence and 
excessive activity of myofibroblasts is associated with the abnormal accumulation of ECM 
components in injured and diseased tissue 135, 136. Moreover, MSTN has been shown to induce 
procollagen (type Iα1, Iα2, and IIIα1) mRNA and FN protein expression by PP1 fibroblasts. 
Given the results collected in our in vitro study, we hypothesized that a lack of MSTN in 
knockout mice would decrease the proliferation of fibroblasts and reduce their production of 
collagenous tissue in injured skeletal muscle. This was made evident by a significant decrease in 
the formation of fibrosis in MSTN-/- mice at 2 and 4 weeks after injury when compared to WT 
mice. McCroskery et al., recently confirmed the correlation of MSTN expression to the 
formation of fibrosis by showing less fibrosis formation in the notexin-damaged tibialis anterior 
(TA) muscle in MSTN-/- mice 4 weeks after injury as compared to WT mice 137. Moreover, we 
found an elevated expression level of DCN, an inhibitor of TGF-β1, in injured MSTN-/- skeletal 
muscles compared to injured WT muscles at 2 weeks after injury. In accordance with this result, 
increased DCN mRNA has been observed in regenerating MSTN-/- muscle 137. Increased DCN 
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might inhibit the effect of TGF-β1, thereby partially explaining the reduced fibrosis and 
enhanced regeneration in injured MSTN-/- muscle.  
3.4.2 Improved Muscle Healing in the Injured MSTN-/- Muscle 
Satellite cells serve as a reservoir of myogenic progenitor cells for the repair and maintenance of 
skeletal muscle. MSTN negatively regulates self-renewal and differentiation of satellite cells 47, 
and decreases the expression of members of the basic helix-loop-helix muscle regulatory factors 
(MRF) (MyoD, Myf5, mrf4, myogenin) 48, 58. MSTN-/- mice show an increased number of 
satellite cells activated and differentiated toward a myogenic lineage 47. In this study, our data 
demonstrates that MSTN-/- mice contain regenerating myofibers with significantly larger 
diameters than WT mice at 2 and 4 weeks after GM laceration. The increased number of satellite 
cells in MSTN-/- mice could, in part, explain the enhanced regeneration revealed by the larger 
diameter of regenerated myofibers in MSTN-/- mice compared to WT mice. Indeed, it has been 
reported that blocking MSTN signals by isolating myoblasts from transgenic mice carrying the 
mutated MSTN receptor results in improved success of myoblast transplantation in mdx mice 
compared to normal myoblasts 122. Furthermore, high levels of MSTN protein have been 
reported within necrotic fibers in the skeletal muscles of rats damaged by notexin 138, and 
western blot analysis revealed the upregulation of MSTN protein at early time-points following 
notexin-induced injury in rat skeletal muscle 139. Interestingly, it has been shown that MSTN 
interferes with the chemotaxis of macrophages in vitro 137; recombinant MSTN protein 
significantly reduces the migration of macrophages and myoblasts toward chemoattracants in 
vitro, which likely promotes skeletal muscle regeneration 137. These results suggest that MSTN 
could impede recruitment of macrophages and myoblasts into the injured site in vivo. 
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Macrophages infiltrate damaged tissue to remove debris that could hinder muscle regeneration. 
Macrophages also secrete a variety of growth factors and cytokines that have chemotactic and/or 
mitogenic effects on muscle precursor cells thereby accelerating muscle regeneration 140-144. 
Compared with WT mice, MSTN-/- mice have shown elevated recruitment of macrophages and 
myoblasts and an accelerated inflammatory response after muscle injury 137. These results 
suggest that the earlier initiation of skeletal muscle regeneration in the injured skeletal muscle of 
MSTN-/- mice compared to the injured muscle of WT mice may be due, in part, to accelerated 
removal of muscle debris. During skeletal muscle healing (following active muscle regeneration 
at early time-points after injury) fibrosis initiates about one week post injury, and peaks at four 
weeks 8, 40, 145. Li et al. 16 reported that some regenerating myofibers probably differentiate into 
myofibroblasts to contribute the formation of fibrosis. This correlation between fibrosis 
development and intense MSTN signaling—and TGF-β1 expression 16 in the early phase of 
healing may suggest the differentiation of regenerating myotubes/myofibers into myofibroblasts. 
Consequently, MSTN protein might modulate the muscle fiber regeneration process through the 
early events of phagocytosis and inflammation 138 and later control myofiber maturation. In this 
way, MSTN seems to act as a regulatory molecule that is produced by the tissue to specifically 
suppress and control the size of muscle growth and development 146.  
3.4.3 Relationships between TGF-β1 and MSTN 
As members of the TGF-β superfamily, TGF-β1 and MSTN share many similarities in structure, 
signaling pathway, and function 64, 65. It has also been shown that TGF-β1 plays a critical role in 
skeletal muscle fibrosis after injury 16, 28-30, 32, 147-149. Since both TGF-β1 and MSTN promote 
fibrosis, it is very important to understand the potential relationships between these two 
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molecules. Recent reports demonstrated that exogenous TGF-β1 strongly stimulated the 
expression of MSTN in C2C12 myoblasts 131. In fact, our in vitro data shows that TGF-β1 
increases MSTN expression in C2C12 myoblasts (and vice-versa), and TGF-β1 and MSTN are 
found to co-localize in the same myofibers shortly after MSTN injection or after injury. We 
found that MSTN is able to induce its autocrine expression in both fibroblasts and myoblasts. In 
the presence of soluble TβRII, MSTN autocrine expression in fibroblasts is decreased. We have 
known that MSTN inhibits C2C12 myoblast differentiation. When TGF-β1 receptors type II 
(TβRII) is blocked by soluble TβRII, MSTN’s ability to inhibit C2C12 myoblast differentiation 
is reduced. Apart from that, quantitative RT-PCR results show that MSTN also stimulates TGF-
β1 mRNA expression in PP1 fibroblasts. Our previous study has shown that TGF-β1 is able to 
induce autocrine expression of TGF-β1 in C2C12 myoblasts 16, nevertheless, our present data 
revealed that TGF-β1 failed to induce its autocrine expression in MSTN-/- primary muscle cells. 
Taken together, these results show that TGF-β1 and MSTN may target different cell membrane 
receptors 65, but can also bind to the same receptor, suggesting that their signaling appears to be 
somehow related. It is likely, then, that the inducement of skeletal muscle fibrosis by TGF-β1 is 
partially mediated by its interaction with MSTN. However, the mechanism by which TGF-β1 
interacts with MSTN to cause fibrosis warrants further investigation.  
3.4.4 Inhibitory Effects on DCN on MSTN 
DCN, a small chondroitin-dermatan sulphate leucine-rich proteoglycan, exists ubiquitously in the 
ECM. Due to its binding to and inhibition of TGF-β1, DCN has been used as a potent antifibrosis 
agent in various organs and tissues 28, 29, 39, 72, 129, 130, including skeletal muscle 28, 29. However, 
DCN’s ability to regulate MSTN activity is still unknown. DCN, which is composed of a core 
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protein and a single glycosaminoglycan chain 66, 67, has the ability to bind to TGF-β1 due to the 
fact that the core protein of DCN contains two binding sites for TGF-β1 70. Similarly, Miura et al. 
have shown that DCN, or the core protein of DCN, directly binds to active MSTN molecules to 
block MSTN-mediated inhibition of C2C12 myoblast proliferation 150. The actual location of the 
MSTN binding site in the DCN core protein and evidence that shows whether TGF-β1 and 
MSTN competitively bind to DCN is topics for further investigation. Of further interest is the 
possibility that DCN may regulate MSTN by influencing another intermediate molecule like 
FLST, an antagonist of MSTN 82. Our results not only show that DCN reduces the effects of 
MSTN on fibroblasts and myoblasts, but also indicates that it stimulates the expression of FLST 
in C2C12 myoblasts. Exogenous FLST then stimulates C2C12 myoblast differentiation, which is 
probably due to FLST’s neutralization of endogenous MSTN. These results indicate that the 
effect of DCN on MSTN may be related to the up-regulation of FLST, which would 
consequently suppress MSTN activity. Nevertheless, more experiments, for example, the effect 
of DCN on FLST knockout cells, need to be done to establish the role of FLST in DCN inhibited 
MSTN activity. Furthermore, we have shown that TGF-β1 probably plays a role in the MSTN 
signaling pathway since TGF-β1 soluble receptor antagonizes, at least in part, the effect of 
myostatin on muscle cells. Overall, DCN probably regulates MSTN activity via three ways: (i) 
directly binding MSTN; (ii) indirectly downregulate MSTN by binding to TGF-β1; and, (iii) 
indirectly down-regulating MSTN by stimulating FLST expression.  
  41
3.5 CONCLUSIONS 
In summary, our results suggest the following: (i) MSTN stimulates the formation of fibrosis in 
skeletal muscle after injury; (ii) TGF-β1 and MSTN up-regulate the expression level of each 
other; and, (iii) DCN is capable of inhibiting MSTN activity as it does for TGF-β1 (Figure 3-6). 
These results, combined with the fact that TGF-β1 plays a key role in skeletal muscle fibrosis 
and that DCN reduces fibrosis in injured skeletal muscle, suggest that TGF-β1 and MSTN 
probably act together; they synergistically amplify the fibrotic process in injured or diseased 
skeletal muscles resulting in greater fibrosis than either could induce individually. Our findings 
may help to further increase the understanding of the mechanism by which MSTN-/- mice show 
decreased fibrosis and enhanced regeneration after injury and suggest that the inhibition of 
MSTN might be a new therapeutic approach for improving skeletal muscle healing through 
enhancement of regeneration and reduction of fibrosis. 
 
Figure 3-6 Relationship between Decorin, TGF-β1, Myostatin, and Follistatin 
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4.0 AAV-MEDIATED MYOSTATIN PROPEPTIDE IMPROVED SKELETAL MUSCLE 
HEALING IN NORMAL MICE AND ATTENUATED DYSTROPHIC PATHOLOGY IN 
MDX/SCID MICE 
4.1 INTRODUCTION 
Since MSTN negatively regulates the growth and development of fetal and adult skeletal 
muscle49, various therapeutic strategies for treating muscle dystrophies or muscle wasting have 
been developed to target MSTN. The mdx mouse is a model for Duchenne and Becker muscular 
dystrophy which mimics dystrophic pathology of muscular dystrophic patients, such as repeated 
muscle damage and regeneration, along with accumulating fibrotic and fatty tissues. Research 
has shown that mdx mice with MSTN knockout are physically stronger, with a greater muscle 
mass, less fibrosis, and a superior capacity for skeletal muscle regeneration 123. Similar 
functional and histopathological improvements were observed in mdx mice treated with MSTN 
blocking antibody and recombinant myostain propeptide (MPRO) 77, 151. Subsequently, a variety 
of inhibitors of MSTN have been identified, including a MSTN blocking antibody, MSTN 
MPRO 56, 57, 73, 152, follistatin (FLST)56, 73, follistatin-related genes 152, growth and differentiation 
factor-associated serum protein-1153, and soluble activin type IIB receptor (ACVR2B) 154.  
            Several groups, including ours, have found that MSTN positively regulates  the formation 
of skeletal muscle fibrosis, much as is the case with TGF-β1 123, 127, 137, 155. Consistent with this 
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are the findings that  recombinant MSTN protein stimulates fibroblast to proliferate and 
synthesize TGF- β1, and fibrotic proteins such as fibronectin, and collagen types I and III 127. In 
vivo, injured MSTN-/- skeletal muscles not only exhibit improved muscle regeneration, but also 
develop significantly less fibrosis after injury than their wide-type controls; this is in part 
because MSTN carries out a signal transduction similar to the pro-fibrotic signaling of TGF-β1 
65; in fact, is appears that TGF-β1 and MSTN act synergistically 127, 131 to induce fibrosis in the 
injured muscle 127.MSTN is therefore an ideal therapeutic target for enhancing the regeneration 
and reducing the fibrosis of the injured and diseased skeletal muscle.  
            Different research groups have shown that an overexpression of MPRO in transgenic 
animals increases muscle regeneration 55-57. Although the amount of increase in muscle mass 
may vary, it appears to be proportional to levels of transgene expression 56, 57. It was also found 
that recombinant MPRO binds to MSTN and antagonizes its biological activity 74, 75, so that the 
local and systemic administration of MPRO can each successfully block MSTN activity and 
attenuate the severity of skeletal muscle dystrophy 77, 156, 157. In this current study, we investigate 
how skeletal muscle healing improves by eliminating MSTN signaling in MSTN-/- mice. We 
also use adeno-associated virus serotype 2 (AAV2) to intramuscularly deliver MPRO into 
skeletal muscle and examine whether a gene transfer-mediated constitutive expression of MPRO 
improves skeletal muscle healing in normal as well as mdx/SCID mice. 
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4.2 METHODS 
4.2.1 Construction of an AAV Vector Carrying Mouse MPRO Gene  
The AAV2-MPRO particle, encoding a mouse MSTN propeptide (MPRO) sequence under the 
control of the cytomegalovirus (CMV) promoter, was generated in following a co-transfection 
methods described previously 158. We used PCR to amplify MPRO cDNA, and then cloned it 
into a CMV promoter-driven AAV vector plasmid. A schematic illustration of CMV-MPRO gene 
cassette is shown in the Figure 4-4A. A pair of primers was designed to amplify the gene segment 
spanning CMV and MPRO gene to detect AAV2-MPRO transcription as indicated in Figure 4-4 
A. The sequences of primers for cmv-mpro are: forward: AAGCTGCAGAAGTTGGTCG, 
backward: AGTGGAGGCGCTCTTGGC. In vitro expression of AAV-MPRO in C2C12 
myoblasts was examined by RT-PCR. 
4.2.2 Transduction of AAV2-MPRO/GFP in Vitro  
C2C12 myoblasts were plated onto collagen-coated 12-well plates for overnight, and then were 
infected with an MPRO-carrying vector at a dose of 106 AAV2-MPRO viral genome (v.g.)/cell. 
The cells then were cultured for 4 more days in low serum medium. Following fixation of cells, 
myosin heavy chain (MyHC) immunostain was performed to monitor myotubes, and the fusion 
index was calculated by determining the ratio of nuclei within fused myotubes (≥ 2 nuclei) to the 
total number of nuclei.    
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4.2.3 Western Blot 
Western blot was performed as previously described at the section 3.2.3.. Primary antibodies, 
mouse anti-MyoD (554130, 1:250; Pharmingen), anti-myogenin (556358, 1:250; Pharmingen), 
and goat anti-Myf5 (1:100, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), mouse anti-β-actin 
(loading control, 1:8000, Sigma) was applied on membranes for overnight. Next day, after 
sufficient wash, membrane was incubated with the horse-radish peroxidase (HRP)-conjugated 
secondary antibodies (Pierce, Rockford, IL) were diluted to 1:5000 and applied. HRP activity 
was determined by its reaction with SuperSignal West Pico chemiluminescent substrate (Pierce), 
and finally positive bands were visualized on X-ray film in a dark room.  
4.2.4 Transduction of AAV2-MPRO or GFP into WT Mice  
Ten female C57BL/6 wide-type (WT) mice at eight weeks of age were used for these 
experiments. Fifty μl of AAV2-MPRO (2.5x1012 v.g./ml) was injected into both GMs of five 
mice, while the same amount of phosphate buffered saline (PBS) was injected into the GMs of 
the other 5 mice as controls. One month after AAV2 vector transduction, both GMs of each 
mouse were subjected to laceration injury. Mice were sacrificed at 4 weeks after laceration. The 
GMs were then harvested, snap-frozen in the liquid nitrogen, and stored in -80o. CD31 staining 
was used to assess whether an MPRO overexpression would increase angiogenesis in the injured 
muscle when compared to the WT control.  
            In a long-term study, GMs of 2 female C57BL/6 WT mice (8 weeks old, n = 4) were 
injected with 50 μl of AAV2-MPRO (2.5x1012 v.g./ml), whereas, the same dose of AAV2-GFP 
was injected into GMs of 2 female littermates (n = 4) as control, similarly, which was followed 
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by bilateral laceration of GMs at 4 weeks after virus transduction. Mice were then sacrificed at 
one year post-injury. The GMs were also harvested, snap-frozen in the liquid nitrogen, and 
stored in -80o. Muscle regeneration and fibrosis were measured for the animals in the both sets of 
experiments according to a published protocol 127.  
4.2.5 Isolation of Muscle Progenitor Cells from WT and MSTN-/- Mice and Cell 
Transplantation  
Muscle progenitor cells (MPCs) were isolated based on their properties of slow-adhering to 
collagen-coated flask using a published modified preplate technique. We isolated 5 WT MPCs 
from 5 male neonatal C57BL/6J mice as well as 5 populations of MSTN-/- MPCs from 5 male 
neonatal MSTN-/- mice with the same background as WT mice. We used an anatomical sex 
technique to determine the gender of neonatal mice. Briefly, new born mice were sacrificed, and 
both upper and lower limbs were harvested. After removal of skin, bone, cartilage, remaining 
muscles were subjected to sequential enzymatic digestions including: collagenase type XI, 
dispase, and trypsin. The resulting muscle cell extracts were then seeded on collagen-coated 
flasks. Different cell populations were obtained by replating the extracts after different time 
intervals (2h (PP1), 24h (PP2), 24h (PP3), 24h (PP4), 24h (PP5), and 72h (PP6)). PP1 cells are 
fibroblasts. The earlier preplate populations (PP2-5) were mainly composed of myoblasts and 
satellite cells, whereas the late preplate population attached to flask after the last 72h cells (PP6) 
enriches MPCs 113, 125, 126, 159. Late preplate cells were collected as MPCs, grew at a low density 
in proliferation medium (PM) consisting of Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen), 10% horse serum (HS; Invitrogen), 10% fetal bovine serum (FBS; Invitrogen), 1% 
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penicillin/streptomycin (P/S; Invitrogen), and 0.5% chicken embryo extract (CEE, Accurate 
Chemical & Scientific Corporation, Westbury, NY) (Figure 4-1).  
 
Figure 4-1 Schematic Illustration of Preplate Technique 
We expanded WT and MSTN-/- MPC population in vitro in PM. When cells reach certain 
numbers, we trypsinized cells, washed them with PBS, and then counted them with a 
hemocytometer. We transplanted MPC population into GMs of female mdx/SCID mice, which 
were generated by crossing mdx (C57BL/10ScSn-Dmdmdx, Jackson laboratory) and SCID mice 
(C57BL/6J-prkdcscid/SzJ mice, Jackson laboratory) at the animal facility of our institution. Each 
MPC population was transplanted in to 4 legs of mdx/SCID so that variability among different 
gastrocnemius muscles (GMs) and mdx/SCID mice can be reduced. Around 300,000 MPCs were 
transplanted into each GM of female mice. At two weeks after cell transplantation, mice were 
sacrificed, and GMs were harvested and cyrosectioned. Dystrophin immunostain was performed 
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and the number of dystrophin-positive was used to evaluate muscle regeneration capacity of 
transplanted donor cells.  
4.2.6 Intramuscular Transduction of AAV2-MPRO/GFP into Mdx/SCID Mice Followed 
by WT MPC Transplantation 
To evaluate whether blockade of MSTN signaling in host dystrophic muscle by MPRO can 
improve regeneration capacity of MPCs, AAV2-MPRO (2.5x1012 v.g./ml) in 50 µl of PBS was 
injected into both GMs of 3 mdx/SCID mice (4 weeks of age, n = 6) 4 weeks prior to cell 
transplantation; while 3 littermates received the same dose of AAV2-GFP (n = 6) as controls. 
Muscle progenitor cells (MPCs) isolated from skeletal muscle of wild-type mice C57BL/6 WT 
mice were transplanted into both AAV-MPRO and AAV-GFP transduced GMs (300,000 cells 
per GM). Before cell transplantation, The MPCs were trypsinized and characterized by flow 
cytometry for CD34 and Sca-1 expression. To label these cells, non-specific binding to MPCs 
were blocked with 10% mouse serum, and then incubate with rat anti-mouse Sca-1 PE and 
biotinylated CD34 monoclonal antibody (ABCAME) followed by an incubation with 
streptavidin (SA)-APC (Pharmingen). Control cells were treated with corresponding isotype 
control antibodies. Before analysis, 7-amino-actinomycin D was added to exclude the 
nonviables. Flow cytometry with a cell sorter (FACStar Plus or FACSAria; Becton Dickinson) 
was used to determine percentage of CD34 and Sca-1 positive cells. Moreover, MPCs’ desmin 
expression and myogenic differentiation capacity were evaluated by immunocytochemistry. For 
examination of desmin, MPCs were plated on 12 well plates at a density of 10,000 cells per well, 
and cells grew in PM for overnight before staining. Moreover, for myogenic differentiation test, 
MPCs were plated on 12 well plates (20,000 cells per well) with DMEM supplemented with 2% 
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FBS (low serum concentration stimulates myotube differentiation) and cultured for 4 days when 
myotubes were extensively formed. Prior to staining, cells were fixed by pre-cooled methanol for 
2 min,  blocked with 10% horse serum for 30 min, and then incubated with a mouse anti-desmin 
antibody, or a mouse anti-myosin heavy chain (MyHC) antibody (1:250,M-4276, Sigma) for 2 
hours. The primary antibodies were detected with a secondary anti-mouse IgG antibody 
conjugated with Cy3 (1:300, C2181, Sigma) for 1h. The nuclei were stained by DAPI staining. 
The percentage of desmin positive cells was determined. The myogenic differentiation capacity 
was measured by fusion index. 
After two additional weeks post cell transplantation, mice were sacrificed and GMs were 
harvested for immunohistochemistry and histological examination. MPC transplantation 
efficiency was measured by the number of dystropin-positive myofibers in host muscles. Fibrosis 
was determined by Masson’s trichrome staining; muscle regeneration was evaluated after H&E 
staining; in a separate experiment, mdx/SCID mice were sacrificed 3 months post AAV-
MPRO/GFP injection.  
4.2.7 Immunohistochemistry   
To stain CD31 or dystrophin, tissue sections were fixed in 4% formalin for 5 minutes followed 
by two 10-minute washes with PBS. The sections were then blocked with 10% HS for 1 hour. 
The rat CD31 primary antibody (BD Pharmingen) was diluted 1:150 in 2% HS, or a rabbit 
dystrophin primary antibody (1:400, Abcam) and incubated with sections for 1h at room 
temperature. The sections were washed three times with PBS and then incubated with the 
corresponding secondary antibody, rabbit anti-rat IgG conjugated with 555 (red, Invitrogen) or 
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donkey anti-rabbit IgG conjugated with 594 (red, Invitrogen) for 30 minutes. Dapi was used to 
stain the nuclei.   
To perform MPRO and coll IV double-immunostain, tissue sections were fixed and 
blocked following standard protocol as described above. Sections were then incubated overnight 
at 4oC in a goat MPRO antibody (2.5 ug/ml, RnD system) that was diluted in 5% donkey serum. 
The following day, these sections were washed with PBS and incubated with the secondary 
antibodies, rabbit anti-Goat IgG conjugated with 594 (red, Invitrogen). After finishing MPRO 
staining, sections were blocked again prior to the use of coll IV primary antibody. Rabbit anti-
Coll IV IgG (1:250, Biodesign International, Saco, ME) in 5% serum was applied on section for 
1h at RT followed by PBS washes and incubation with donkey anti-rabbit IgG conjugated with 
488 (green, Invitrogen).  
4.2.8 Statistics 
All of the results from this study are expressed as the mean ± standard deviation (SD) or mean  ± 
error of the mean (SEM). The differences between means were considered statistically 
significant if Ρ < 0.05. The Student’s t-test was used to compare the difference between two 
groups. Error bars on the graphs represent the SD or SEM. * represents  Ρ < 0.05, and ** 
represents Ρ < 0.01.  
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4.3 RESULTS 
4.3.1 MSTN-/- Muscles Exhibited Increased Neovascularization 
 
Figure 4-2 Earlier Neovascularization in the Injured MSTN-/- Muscle 
At 3, 5, 7 days after laceration injury, frozen sections of injured WT and MSTN-/- muscles were subjected to HE 
stain and double immunostain: MyHC (green,) and CD31 (red). HE stains parallel to images of immunostaining 
show the process of muscle healing after injury. (A, A’) At day 3, ruptured myofibers degraded, and numerous 
inflammatory cells invaded into the injured site. A few residues of necrotic myofibers (green, arrows) were detected 
in the injured WT and MSTN-/- muscle. (B, B’) At day 5, muscle degeneration continued, CD31-positive capillary 
was absent at CZ (arrowheads) of the injured sites. (C) At day 7, CZ of the injured WT muscle was filled with 
disorganized connective tissue; capillary remained absent from CZ (arrowheads). In contrast, in the MSTN-/- 
injured muscle (C’), some regenerating myofibers pierce into CZ and the ingrowth of CD31-positive capillaries was 
also detected.   
 
To investigate the underlying mechanisms by which blocking MSTN signaling promotes skeletal 
muscle healing, we compared neovascularization between these injured muscles of WT and 
MSTN-/- mice. CD31 (endothelial maker, red) and myosin heavy chain (MyHC, green) staining 
were carried out to determined the injured site and the extent of vacularity in the injured muscles. 
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Day 3 post-laceration, we can observe numerous mononucleated cells and myofiber debris 
(arrows) in both kinds of injured muscles (Figure 4-2 A, A’). At day 5, capillary was absent in 
central wounds of WT and MSTN-/- muscle as delineated by white arrowheads (Figure 4-2 B-
B’). At 7 days post-injury, CZ of MSTN-/- muscle had started to be neovascularized through 
ingrowth of capillaries from periphery of the wound and newly regenerated myofibers had 
penetrated into central of the wound (arrows, Figure 4-2 C’), whereas there remained deficiency 
of blood vessel in the central wound of WT muscle (arrowheads, Figure 4-2 C). Corresponding 
H&E stain showed the histology of injured muscles at different time points after injury. At 4 
weeks, CD31-positive blood vessels were seen irregularly scattered in the injured WT muscle, 
whereas blood vessels were more evenly distributed in the injured MSTN-/- muscle, suggesting a 
more mature pattern of neovascularization in injured MSTN-/- muscle. A quantitative analysis 
demonstrated that injured MSTN-/- muscle showed a significantly higher capillary density than 
did the WT control (Figure 4-3).    
 
Figure 4-3 Increased Vascularity in Injured MSTN-/- Muscle at 4 weeks after Laceration 
CD31 immunostain demonstrate that there is a significant increase in CD31 positive capillaries in injured MSTN-/- 
muscle compared to control (Mean ± SD; ** P < 0.01). 
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4.3.2 Delivery of AAV2-MPRO Inhibits MSTN Activity in Vitro  
In this study, we used an adeno-associated virus (AAV) vector serotype 2 to deliver the MPRO 
to myoblasts in vitro and a direct injection of the virus to deliver the MPRO to the gastrocnemius 
muscle (GM) in vivo. In vitro, the RT-PCR result indicated that MPRO gene was successfully 
expressed in C2C12 myoblasts (Figure 4-4 A). The MPRO effectively neutralized the MSTN 
and stimulated the differentiation of C2C12 myoblasts. In contrast to non-transduced C2C12 
myoblasts, AAV2-MPRO-transduced myoblasts readily fused into larger myotubes containing 
numerous myonuclei (Figure 4-4 B). The addition of AAV2-MPRO led to a significant increase 
in the cells’ fusion index in culture (Figure 4-4 B). Moreover, an overexpression of MPRO 
stimulated the expression of Myf5 and myogenin in C2C12 myoblasts in differentiation medium 
without affecting MyoD expression (Figure 4-4 C).  
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 Figure 4-4 In Vitro AAV-MPRO Transduction 
(A) The schematic illustration shows the CMV-MPRO construct. The expression of AAV-MPRO by C2C12 
myoblasts was detected by RT-PCR. (B) After induction of myogenic fusion in low-serum medium, C2C12 
myoblasts expressing AAV-MRPO were fixed and stained with MyHC (red); nuclei were stained with Dapi (blue).  
AAV-MPRO transduction resulted in the formation of larger MyHC-positive multinucleated myotubes and a 
significant increase in fusion index (Mean ± SD; * P < 0.05). (C) AAV-MPRO stimulated the expression of 
myogenic regulatory factors, Myf-5 and myogenin, but not MyoD. 
 
4.3.3 AAV2 Delivered-MPRO Inhibits MSTN Activity in Vivo 
We then transduced AAV2-MPRO into the murine skeletal muscle to examine whether an AAV-
delivered MPRO gene could be stably expressed in vivo and improve the skeletal muscle healing 
after injury. We injected the AAV-MPRO into the GMs of adult BL6J mice; the same amounts 
of PBS were injected into littermates as the control. Four weeks after the AAV2 vector delivery, 
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we lacerated both GMs of each mouse. Mice were sacrificed at 4 weeks post-injury. Masson’s 
trichrome histochemistry showed extensive fibrosis infiltration in injured WT skeletal muscle, 
while fibrosis in injured AAV-MPRO transduced muscle was limited with a reduced amount of 
fibrotic tissue (Figure 4-5 A). An MPRO overexpression significantly suppressed the formation 
of fibrous scar tissue in the injured AAV2-MPRO transduced GMs as compared to that in the WT 
counterpart (2.64 ± 1.04 vs. 7.21 ± 1.06; mean ± SD, ** P < 0.01) (Figure 4-5 B). The expression of 
the MPRO in AAV-MPRO transduced muscles indicated that genes delivered by the AAV were 
stably expressed in muscle (Figure 4-5 C). The weight of AAV2-MPRO transduced-GMs was 
also significantly higher than that of the WT counterparts (Figure 4-5 D). We also observed 
larger regenerating myofibers in the AAV2-MPRO transduced injured muscle than in the injured 
WT muscle (Figure 4-5 E). The mean diameter of regenerating myofibers in the GMs 
overexpressing MPRO was increased 26.7% over that in the non-transduced GMs, and the 
difference was significant (36.79 ± 3.79 vs. 29.03 ± 2.18; mean ± SD, **P < 0.01) (Figure 4-5 
F). Correspondingly, the distribution of diameter of regenerating myofibers revealed that 78% of 
regenerating myofiber in control muscle had a diameter smaller than 35 µm when compared to 
46.28 % of that in AAV2-MPRO transduced muscle; in contrast, 53.7% of regenerating myofibers 
in injured AAV-MPRO transduced muscle had a diameter in the range of 35 to 70 µm (Figure 4-
5 G).  
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 Figure 4-5 AAV-MPRO Improved Skeletal Muscles Healing at 4 Weeks after Injury 
 (A) Masson trichrome staining show extensive fibrotic tissue (blue) at the injured site of the muscles treated with 
PBS, whereas fibrotic tissue was mostly limited to the surface of the injured site of AAV-treated injured muscle. (B) 
Consequently, the fibrosis in the AAV-MPRO treated injured muscle was significantly decreased in comparison to 
PBS control. (C) Coll IV (green) and MPRO (red) double-staining showed strong MPRO signal in the cytoplasm of 
fibers of AAV-MPRO transduced muscle. PBS injected muscle was a negative control. (D) When injured muscles 
were harvested at 4 weeks after injury, we found that AAV-MPRO transduced GMs gained significantly more 
weight over PBS control. (E) HE stain revealed obvious muscle hypertrophy in AAV-MPRO treated injured muscle. 
(F) The increase in the diameter of regenerating myofibers resulted from MPRO was significant (Mean ± SD; ** P < 
0.01). (G) Frequency histograms show the regenerating myofiber diameter distribution in the AAV-MPRO treated 
and control muscle. 
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Figure 4-6 Increased Angiogenesis in AAV-MPRO Treated Injured Skeletal Muscle 
(A) HE stain show abundant disorganized connective tissue (black arrowheads) in the superficial zone of injured site 
of AAV-GPF treated muscle, while in the injured AAV-MPRO treated muscle, regenerating fibers (black 
arrowheads) ingrown into injured site replaced connective tissue. Inserts are enlarged images in the frames.  (B) 
MyHC (green) and CD31 (red) double-immunostaining of parallel slides confirmed the absence of myofibers in 
injured site (white arrowheads) corresponding to the connective tissue of AAV-GFP treated injured muscle. 
Moreover, we observe CD31-positive capillaries scattered among the MyHC-positive regenerating myofibers. (C) 
CD31-staining (red) alone indicated a higher density of CD31 positive capillaries in the AAV-MPRO treated injured 
muscle than that in AAV-GFP treated muscle. The increase in angiogenesis in the former is significant (Mean ± SD; 
** P < 0.01). 
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In addition, we also found increased vascularity in the AAV2-MPRO-transduced mice after the 
GM laceration; Fig.4 shows the representative images from the injured AAV-MPRO transduced 
muscle and the control. In efforts to clarify the mechanism of how a blockade of the MSTN 
signal via the MPRO improved muscle healing, we investigated whether the MPRO 
overexpressing injured muscle exhibited more CD31 positive capillaries.  The H & E stain 
showed the histology of injured skeletal muscles (Figure 4-6 A). The MyHC-CD31 double stain 
showed regenerated myofibers interspersed with CD31 positive capillaries at the injured site 
(Figure 4-6 B). The CD31 stain alone revealed a higher density of capillaries in the MPRO 
overexpressing injured mucles than in their counterparts (Figure 4-6 C). We consequently found 
significantly more CD31 positive capillaries in the AAV-MPRO transduced injured muscle than 
in the control at 4 weeks post-injury (Figure 4-6 D). 
4.3.4 Long Term Beneficial Effects of MPRO on Muscle Healing 
In a separate study, we injected the AAV-GFP and the AAV-MPRO into the GMs of different 
littermates 4 weeks prior to laceration injury, but they were not sacrificed until one year after the 
muscle laceration. We were able to still detect strong expressions of the GFP and MPRO in the 
myofibers of the AAV-GFP or MPRO transduced muscles, respectively. We observed the GFP-
positive fibers in the AAV-GFP treated muscle, but not in the AAV-MPRO treated muscle 
(Figure 4-7A). Collagen type IV staining shows the outlines of myofibers; MPRO-positive 
myofibers (arrowheads) indicate a constitutive expression of MPRO in skeletal muscles 
transduced with the AAV-MPRO, but not in the AAV-GFP control muscle (Figure 4-7A). Many 
regenerating myofibers remained centronucleated in muscles overexpressing GFP or MPRO 1 
year post-injury (Figure 4-7 B).   Many regenerating myofibers remained centronucleated in 
  59
muscles overexpressing GFP or MPRO 1 year post-injury (Figure 4-7 B). We observed 
significantly larger regenerating myofibers in the AAV2-MPRO transduced injured muscle than 
in the controls (Figure 4-7 B).                         
 
Figure 4-7 AAV-MPRO Showed Long-Term Beneficial Effects on the Injured Skeletal Muscle 
(A) Images show the expression of GFP (green) in the AAV-GFP treated muscle at 1 years post injury in contrast to 
the absence of GFP signal in AAV-MPRO treated muscle. In the lower images, coll IV immunostaining (green) 
highlights each individual muscle fibers. MPRO immunstaining reveals MPRO expression in the cytoplasms of 
myofibers of AAV-MPRO treated muscles, while the AAV-GFP treated muscle serve as a negative control. (B) 
Constitutive expression of MPRO in the AAV-MPRO treated muscle continued to cause muscle hypertrophy after 
muscle injury. Larger central nucleated myofibers can be observed in the AAV-MPRO treated injured muscle as 
compared to the control. The mean diameter of regenerating myofibers in the former was significantly increased. (C) 
Distribution of diameters of regenerating myofibers in the AAV-GFP and –MPRO treated injured mucle. (D) 
Weight of injured muscle transduced with AAV-MPRO was higher than the control (Mean ± SD; * P < 0.05). 
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Frequency histogram indicated that the AAV-MPRO transduced injured muscles contained a 
greater percentage of regenerating myofibers that have larger diameters; for instance, only 30% 
of the regenerating myofibers in the control muscle were larger than 50 µm when compared to 
61 % in the AAV2-MPRO transduced muscle (Figure 4-7 C). The blockade of the MSTN by the 
MPRO has a long-term effect with a significant increase in the weight of GMs (Figure 4-7 D).  
4.3.5 Lack of MSTN Signal in Donor MPCs Elevated Efficiency of Cell Transplantation 
in Mdx/SCID Mice 
In efforts to search a robust cell population for cell therapy treating DMD, we investigated 
whether blocking the MSTN signal pathway in donor cells could augment the success of cell 
transplantation. We therefore isolated MPCs from the skeletal muscle of the MSTN-/- mice to 
examine their performance in the recipient dystrophic muscle over the WT MPCs. 
Transplantation of MSTN-/- MPCs into the dystrophic muscle produced more dystrophin-
positive regenerated myofibers, as compared to a few myofiber regenerated from WT-MPCs in 
the control muscle (Figure 4-8 A). We isolated five WT MPC populations and five MSTN-/- 
MPC population from five WT and five MSTN-/- mice, respectively. Each cell population was 
injected into four legs to minimize the variation among different mdx/SCID mice. The mean 
number of dystropin-postive myofibers derived from the same cell population from four leg 
specimens was considered as one sample. Regarding the variability among different cell 
populations, we did observe that some WT MPC population regenerated more myofibers than 
did other MSTN-/- MPC populations (eg., WT#3 > MSTN-/-#3, 2); however, MSTN-/- #2, 
which produced the least number of myofibers among the MSTN-/- MPC populations, exceeded  
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Figure 4-8 Donor MSTN-/- MPCs Exhibited a Higher Regenerative Capacity in the Host Dystrophic Muscle                              
(A) Representative images show that the MSTN-/- MPCs produced numerous dystrophin-positive myofibers (red) in 
dystrophic muscle as compared to a few dystropin-positive fibers seen in dystrophic muscle transplanted with the 
WT MPCs. (B) Both WT and MSTN-/- MPC populations show a great variation in regenerating muscle fibers, 
however, the majority of MSTN-/- MPC population regenerated more dystrophin-positive muscle fibers than all WT 
MPC populations combined. (C) Transplantation of MSTN-/- MPC led to 165% more dystrophin-positive fibers in 
dystrophic GMs than in control dystrophic GMs transplanted with WT MPCs; blocking the MSTN signal in donor 
cells led to a significant increase in dystrophin-positive regenerated muscle fibers (Mean ± SEM; * P < 0.05). 
 
the results of three WT-MPC populations out of the five total populations (Figure 4-8 B). The 
maximum number of myofibers regenerated from the WT-MPC population was 400, whereas 
three out of five MSNT-/- population regenerated more than 400 myofibers, and two MSTN-/- 
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MPC population gave around 800 regenerated myofibers (Figure 4-8 B). As a result, overall 
number of the dystrophin positive regenerated myofibers in MSTN-/- MPC populations 
surpassed that of the WT cells (195.6 ± 65.357 vs. 518.08 ± 117.64; mean ± SEM, *P < 0.05) 
(Figure 4-8 C).  
4.3.6 AAV-MPRO Improved Cell Transplantation and Reduced Severity of Muscular 
Dystrophy Efficiency in Mdx/SCID Mice 
We further examined whether blocking the MSTN in the dystrophic host muscle can facilitate 
donor muscle cell transplantation. We transplanted the MPCs isolated from the WT mice into the 
dystrophic muscles pre-treated with either AAV-GFP or AAV-MPRO 4 weeks prior to cell 
transplantation. In vitro characterization revealed that 70% of MPCs expressed demin, a 
myogenic marker (Figure 4-9 A), suggesting a high myogenic potential of these cells. In the low 
serum medium, the MPCs readily fused and formed into MyHC positive multi-nucleated 
myotubes (Figure 4-9 B, F). A small portion of this MPC population was CD34 and Sca-1 
double positive, which may represent stem cells (Figure 4-9 C, E). An in vivo characterization 
showed that these MPC were able to regenerate dystrophin positive myotubes when injected into 
dystrophic muscle of mdx/SCID (Figure 4-9 F). Two weeks after cell tranplantation, we 
examined whether blocking MSTN signal by MPRO in host muscle increased the efficiency of 
muscle cell transplantation in dystrophic muscles.  The images in in Figure 4-9 G showed the 
representative images of dystrophin positive engraftments in muscles of mdx/SCID mice 2 weeks 
after cell transplantation.  We found that normal MPCs injected into the AAV-MPRO transduced 
dystrophic muscles surpassed the cells injected into the control muscles in regenerating muscle, 
indicated by more dystrophin-positive regenerating myofibers (Figure 4-9 G).  
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 Figure 4-9 Muscle Progenitor Cell Characterization and Transplantation 
 (A, F) MPC population was highly desmin positive, around 70.4%. (B) In a low serum medium, MPCs easily 
differentiated and fused into multinucleated mytubes visualized by MyHC (red) and dapi (blue) staining with a 
fusion index of 74.5% (F). (C, E) Flow cytometry indicated 24% of MPCs are Sca-1 postive, 13.5% CD34, and 7% 
Sca-1 double positive. (D) In vivo characterization showed that MPCs were able to form dystrophin-postive (red) 
myofibers in dystrophic mice. (G) We injected the same numbers of this MPC population into skeletal muscle of 
mdx/SCID mice transduced with the AAV-GFP and -MPRO respectively; the MPCs transplanted into muscle 
regenerated more dystrophic positive myofibers than cells in the control muscle. The increase is significant (Mean ± 
SEM; * P < 0.05). 
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To explore why MPCs transplanted into the AAV-MPRO treated muscles performed better, we 
compared the differences in dystrophic pathology between the GMs of mdx/SCID mice 
transduced with AAV-GFP or MPRO. Cryosectioned muscle samples were subjected to H&E 
and Masson’s trichrome staining at 6 weeks after virus transduction. Histological analysis 
indicated a decreased dystrophic phenotype after the AAV-MPRO treatment. The insets (20x) 
show whole sections of cross-section of GMs (Figure 4-10 A). The arrows in the insets indicate 
that generally more necrotic foci affected by pathological changes were observed in the AAV-
GFP transduced control dystrophic muscle than in the AAV-MPRO treated dystrophic muscle, 
which were poorly stained by eosin (Figure 4-10 A).  The enlarged images (40x) revealed that 
those areas consist of necrotic myofibers, numerous mononucleated cells, connective tissue, or 
small regenerating myofibers. The necrotic myofibers and cellular filtration can be readily 
appreciated in a further enlarged image (100x) of the control muscle (arrows and arrowhead), 
whereas the AAV-MPRO treated muscle exhibited less damages but a lot of regenerating fibers 
(arrows and arrowhead, Figure 4-10 A). Masson’s trichrome stain revealed that the degenerative 
areas were associated with extensive fibrotic tissue (blue). Low (2x) and high (40x)   
magnification images revealed that the control dystrophic muscles generally contain more 
fibrotic tissue than did AAV-MPRO treated dystrophic muscles. A higher levels of fibrosis, 
averaging 7.08% (and varying from 5.32 to 9.02%) by area of GM cross-section affected, is 
detected in the control muscle as compared to 4.09% (and varying from 2.73 to 6.07%) in the 
treated muscle. A significant decrease in fibrous scar tissue in the AAV2-MPRO treated muscles 
was observed as compared to the controls (Figure 4.10 B).   
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 Figure 4-10 Improved Dystrophic Pathology in mdx/SCID Mice after AAV-MPRO Treatment 
(A) Small inserts 2x in upper images (HE) show overall morphology of cross-sectional dystrophic muscles. Small 
arrows in inserts point out poorly stained necrotic foci. More necrotic foci were observed in AAV-GFP treated 
dystrophic muscle than AAV-MPRO treated dystrophic muscle. When necrotic foci were enlarged, we observed 
necrotic myofibers (arrowheads) and numerous mononuclear cells (arrows) in AAV-GFP treated dystrophic muscle, 
but abundant small newly regenerated fibers and less cellular infiltration in AAV-MPRO treated dystrophic muscle. 
(B) Masson’s trichrome staining reveal that the necrotic foci were stained blue suggesting accumulation of fibrotic 
tissue within the foci. (See the additional amplified images.) Measurement of the scar tissue shows that AAV-
MPRO treatment led to a significant decrease in fibrosis of dystrophic muscle (Mean ± SD; * P < 0.01). (C) The 
mean diameter of regenerating myofibers in AAV-MPRO treated muscle is significantly larger than that of AAV-
MPRO treated muscle (Mean ± SD; * P < 0.01). (D)Moreover, this AAV-MPRO induced muscle hypertrophy 
eventually cause a significant increase in muscle weight (Mean ± SD; * P < 0.05). 
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Moreover, hypertrophy in AAV2-MPRO treated dystrophic muscle is noteworthy. Measuring the 
diameter of a single fiber demonstrated that the mean diameter of fibers in the AAV-MPRO 
transduced dystrophic muscles is significantly larger than that of the AAV-GFP transduced 
counterparts (Figure 4-10 C).  The AAV2-MPRO transduction-induced muscle hypertrophy 
eventually led to a significant increase in muscle weight when compared to control (Figure 4-10 
D). Taken together, improvements in dystrophic muscle by the AAV-MPRO were manifested by 
decreases in necrotic foci, fibrosis, and increases in muscle weight and single fiber diameter. 
4.4 DISCUSSION 
After injury, skeletal muscle is able to undergo limited regeneration from myoblasts, satellite 
cells, myogenic progenitor cells, and stem cells; nevertheless, severely injured muscle usually 
ends up with incomplete skeletal muscle healing due to the fact that the ensuing formation of 
fibrosis hinders effective muscle regeneration. Thus, an optimal approach to treat injured muscle 
should not only be able to enhance muscle regeneration, but also reduce the formation of fibrosis.  
            The discovery of the MSTN is a significant breakthrough for the development of 
therapeutic approaches for myopathies. In addition to numerous evidence showing that inhibiting 
MSTN boosts muscle growth and regeneration under pathological conditions, such as with 
muscle injury and dystrophy 77, 123, 127, 137, 151, MSTN also regulates skeletal muscle fibrosis 127, 137, 
155. Without MSTN, as seen with MSTN -/- mice, skeletal muscle fibrosis is significantly lower 
after injury than that observed with WT skeletal muscle 127, 137. While fibroblasts are the main 
source of extracellular matrix (ECM) during the formation of fibrosis, MSTN directly stimulates 
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the proliferation of muscle fibroblasts and their in vitro and in vivo production of ECM 127, 137, 155. 
Therefore, MSTN is an excellent therapeutic target for treating injured and diseased muscles. 
Because the in vivo cytokine networks are very complex, however, the underlying mechanism by 
which MSTN inhibition attenuates muscle fibrosis requires further investigation. For now, it is 
clear that MSTN and TGF-β1 synergistically induce fibrosis after skeletal muscle injury; the 
reduced fibrosis in injured MSTN-/- muscle may results in part, but perhaps not completely, 
from the absence of MSTN 127; whether or not this is indeed the case, however, is not yet entirely 
clear. This may also be related in part to local changes in vascularity.  
4.4.1    Increased Vascularity in the Injured MSTN-/- Skeletal Muscles and AAV-MPRO 
Treated Injured Skeletal Muscles 
As the local tissue vascularity promotes muscle regeneration and helps to reduce the amount of 
fibrosis following injury 124. It is not surprising that we noted an earlier onset of 
neovascularization from the time of injury in the MSTN-/- muscle compared to wild type 
muscle. At 4 weeks after injury, injured MSTN-/- muscle contained significantly more CD31-
positive capillaries than controls. The increased vascularity appears to partially account for 
improved muscle healing in injured MSTN-/- mice. Since the emergence of transgenic animals in 
the last decade, they have become a powerful and exciting research model to study protein 
function and molecular mechanisms through taking advantage of “loss or gain of function”. 
Nevertheless, it is worth mentioning that the irreversible genetic manipulations may result in 
compensatory upregulation, developmental defects, and others. Changes take place during the 
prenatal life which may impose undesired effects on adult animals 160. An alternative 
experimental approach to transgenesis is to use a virus as a gene delivery vehicle carrying the 
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desired cDNA to certain tissues or organs. The Adeno-associated virus (AAV) is garnering 
significant interest as a vector for human gene therapy, due to its lessened immunogenicity and 
ability to efficiently infect differentiated fibers of skeletal muscle and stable long term 
expression of transferred gene 147, 161. In this study, we injected an AAV2-mediated MSTN 
propeptide cDNA into GMs 4 weeks prior to injury to establish a postnatal, muscle specific 
MSTN propeptide overexpression model.  
            Our results suggest that the AAV-MPRO gene could be stably expressed in vivo and 
improve the healing of the injured muscle over a long term. We found that the MPRO gene 
transfer improved skeletal muscle healing by stimulating muscle regeneration and inhibiting 
fibrosis 4 weeks after injury, which coincides with higher density of CD31 positive capillaries in 
the MPRO expressed muscle than in the control. This further suggests that there is a negative 
correlation between MSTN and vascularity in injured skeletal muscle, which is consistent with 
what observed in injured MSTN-/- muscle; nonetheless, it is important to note that the 
mechanisms by which MSTN and vascularity are conversely linked warrant further investigation. 
Our long term study also shows that there is an abundant expression of the GFP and MPRO in 
the skeletal muscles at 1 year after gene transfer. By that time fibrosis nearly disappears in all 
injured muscles, while the hypertrophy of regenerating myofibers in AAV-MPRO transduced 
muscles was still observed, indicating a continuous beneficial effect on myofibers.  
4.4.2 Blocking MSTN-/- Signaling in Muscle Progenitor Cells Improve Cell’s 
Regenerative Capacity 
As much of the pathology involved in traumatic skeletal muscle injury is similar to that involved 
with the pathology of muscular dystrophy, our group has taken a particular interest in the 
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muscular dystrophy with a special emphasis on cell therapy. Cell therapy has received increasing 
attention, since accumulating evidence demonstrates that the transplantation of highly 
proliferative multipotent cells may be able to treat numerous diseases and tissue injuries. One 
such disease is DMD, a lethal sex-linked recessive, muscle-wasting disease stemmed from a 
mutation of the dystrophin gene. The absence of a functional dystropin expression at the 
sarcolemma of myofiber makes it susceptible to contracting forces, and consequently results in 
muscle fiber necrosis and muscle weakness. Although finding an effective treatment for DMD 
will require further research, cell and gene therapies are two therapeutic approaches of great 
interest to the research community. Theoretically, transplanting cells with a normal dystrophin 
gene into dystrophic muscle should be able to partially restore dystrophin and improve DMD. 
Donor myoblasts, especially stem cells, do indeed form dystrophin-positive myofibers in 
dystrophic muscles of mdx mice; significant results, however, have not yet been produced, due to 
obstacles such as poor dissemination, a limited survival of donor cells.   
In order to improve cell therapy for the treatment of diseases such as DMD, it is crucial to 
have donor cells with high quality of performance. Since MSTN negatively regulates the growth 
and development of myofibers, blocking the MSTN signaling of donor cells may significantly 
improve the performance of muscle cells.  In studies performed by Tremblay et al, myoblasts 
that were isolated from transgenic mice and carried a dominant negative form of myostatin 
receptor (dnActRIIB) on average gave rise to 75% more dystropin-positive fibers in recipient 
dystrophic tibialis anterior muscle than did WT myoblasts 122. Similarly, we previously reported 
that muscle regeneration in mdx/SCID mice is superior when their GMs are implanted with 
MSTN-/- as opposed to WT MPCs 127. In the present study, we isolated more MSTN-/- MPC 
populations from different MSTN-/- mice and more extensively compared their competency in 
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cell transplantation to that of the WT MPC populations.  In this comparison, we first found that 
there exists a broad heterogeneity within both WT MPC populations and MSNT-/- in term of the 
capacity of these cells to regenerate muscle.  This heterogeneity likely resulted from variations 
among mice from which cells were isolated, as well as variations among the host mdx/SCID 
mice. We further compared the regenerative capacity of MPCs between WT and MSTN-/- 
population, and found that the MSTN-/- MPCs can produce significantly more dystrophin-
positive myofiber than the WT MPCs. These results suggest that genetically modifying donor 
cells does improve the success of cell transplantation.  
4.4.3 Improved Success of Cell Transplantation by Blocking MSTN Signaling in Host 
Dystrophic Muscle 
It appears that over time, there has been an increasing numbers of biomedical investigators who 
believe that inhibiting MSTN is a therapeutic strategy for treating muscular dystrophy 77, 151, 162. 
Among some of the therapies that have been investigated are the use of an anti-MSTN antibody 
and of a recombinant MSTN propeptide, both of which produce a histological and functional 
improvements in mdx mice 77, 151. Xiao’s group recently reported that the same MPRO cDNA as 
used in this study can be delivered systematically with the AAV-serotype 8 vector to augment 
the skeletal muscle mass of both normal and mdx mice 157.   Moreover, MPRO overexpression 
resulted in less mononuclear cell infiltration and fibrosis as well as lower creatine kinase levels 
in the dystrophic muscle of mdx mice when compared to untreated controls.  157. More 
interestingly, it has been found that blocking MSTN signal transduction in host mdx mice 
significantly enhances muscle regeneration capacity of donor myoblasts 122, 163; Tremblay et al 
have accomplished this by generating transgenic mdx mice with a dominant negative form of 
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MSTN receptor (dnActRIIB), 122 as well as by overexpressing the MSTN inhibitor, follistatin 
(FLST) 163. Normal myoblasts transplanted into these transgenic mdx mice outperformed cells 
transplanted in mdx mice that were not transgenically modified 122, 163. Of note, however, data 
were obtained from experiments using genetically engineered mdx mice, making it difficult to 
translate these findings into the clinical trial.  Moreover, dnActRIIB and FLST are not MSTN-
specific inhibitors, as they also block other growth factors such as activin. By contrast to these 
studies, out study examines the impact of injected MPCs into dystrophic muscles which are not 
transgenically modified, but rather, in which MSTN is blocked by AAV-MPRO. Specifically, the 
AAV-GFP or MPRO construct was injected into the muscles of mdx/SCID mice 4 weeks prior to 
the transplantation of MPCs to investigate whether this AAV-MPRO construct can enhance the 
muscle regeneration potential of donor cells by blocking MSTN signaling.  
Our results indicate that inactivating MSTN in dystrophic host muscle with MPRO 
significantly improves the regeneration that follows MPC transplantation; when compared to the 
AAV-GPF transduced control, the MPRO construct yielded significantly more dystrophin-
positive myofibers. We further observed that MPRO ameliorates the dystrophic pathology of 
mdx mice by reducing collagen deposition, mononuclear cellular infiltration, and promoting 
muscle regeneration; these findings were in sharp contrast to the typical findings of dystrophic 
muscle, in which muscle fibers are gradually replaced by fibrotic and adipose tissue. The 
extensive fibrosis in dystrophic muscle is a likely cause for an ineffective cell transplantation. It 
is possible that a favorable microenvironment for donor cells to promote regeneration is created 
by inhibiting fibrogenesis.  Accordingly, we propose three mechanisms (Figure 4-11) by which 
cell transplantation can be improved, based on our experimental findings. First, MPRO prevents 
MSTN from inhibiting donor cell-mediated myofiber regeneration; in doing so, donor cells may 
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be better able to adapt, proliferate, differentiate, and form dystrophin-positive myofibers. 
Second, MPRO inhibits MSTN, thereby reducing fibrosis and promoting muscle regeneration in 
dystrophic muscle. Finally, the decrease in degenerative foci, fiber necrosis, and moderated 
cellular infiltration may suggest that there are fewer cytotoxic cytokines and substances being 
secreted by inflammatory cells (e.g., neutrophil), such as tumor necrosis factor-α (TNF-α), 
 
Figure 4-11 Schematic Representation of How Transduction of the AAV-MPRO into Host Dystrophic Muscle 
Improves Efficiency of Cell Transplantation 
(1) MPRO inhibits the endogenous MSTN and promotes muscle regeneration in the host dystrophic muscle. (2) 
MPRO reduces fiber necrosis and inflammatory cell infiltration. (3) MPRO reduces fibrosis. The deregulation of 
MSNT on donor cells ameliorated dystrophic physiology and may facilitate donor cells to form more dystrophin-
positive myofiber. 
 
 
superoxide, hypochlorite, and nitric oxide 164-166  in the AAV-MPRO-treated dystrophic muscle. 
Numerous in vitro and in vivo evidences have demonstrated that inflammatory cells (e.g., 
neutrophils and macrophages) are detrimental to healthy muscle cells167-169 and myofibers 170, 171 
(Figure 4.11). 
The primary onset of muscle necrosis in dystrophin-deficient muscle is primarily 
attributed to the increased susceptibility to damage during contraction.  Additionally, typical 
secondary chronic inflammatory response to progressive muscle necrosis further aggravates the 
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symptoms of dystrophinopathies; it has been well documented that an excessive inflammatory 
response can directly cause severe myofiber damage in both dystrophies and myositis 172-175. In 
mdx mice, abrupt skeletal muscle necrosis begins at 21 days and peaks at 28 days of age 176;  
with the an administration of TNF-α neutralizing antibody Remicade®, however, there is a delay 
in the onset of muscle breakdown, as well as a decrease in phagocyte infiltration, fiber necrosis, 
and centronucleated myofibers in mdx mice when compared to controls 164. It has also been 
shown that depleting neutrphils or inhibiting TNF-α by Etanercept reduces the extent of muscle 
necrosis in mdx mice 165. In a similar fashion, our results indicate that MPRO improves the 
dystrophic phenotype in mdx/SCID mice, ultimately enhancing the efficiency of cell 
transplantation. Accordingly, improving the microenvironment of host dystrophic muscle in this 
fashion probably is a feasible approach for enhancing the efficiency of cell transplantation.   
4.5 CONCLUSION 
Our data show that angiogenesis occurs earlier in the injured MSTN-/- muscle than in the injured 
normal muscle after laceration injury. The increased angiogenesis appears to partially account 
for improved muscle healing in injured MSTN-/- mice. Next, we use AAV to deliver MPRO 
cDNA into GMs to restrict MSTN propeptide overexpression in the certain skeletal muscles of 
adult mice. Our results suggest that AAV-MPRO gene could be stably expressed in vivo and 
improve healing process of injured muscle for a long term. We found that MPRO gene transfer 
improved skeletal muscle healing through stimulating muscle regeneration and inhibiting fibrosis 
4 weeks after injury, which coincides with more active angiogenesis in MPRO expression 
muscle than control. It suggests a negative correlation between MSTN and angiogenesis in 
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injured skeletal muscle. However, the clear relationship between MSTN and angiogenesis 
warrants further investigation.    
Furthermore, we found that elimination of MSTN expression in MPCs led to an increase 
in cells’ ablility to regenerate skeletal muscle in the dystrophic muscle of mdx mice. Moreover, 
Inactivation of MSTN in dystrophic host muscle by MPRO significantly improved the success of 
MPC transplantation as compared to the AAV-GFP transduced control, evidenced by 
significantly more dystrophin-positive myofibers in the former. It is probably partially due to the 
fact that MPRO ameliorated the dystrophic pathology of mdx mice by promoting muscle 
regeneration and reducing collagen deposition, and thereby improve milieu in host dystrophic 
muscle and favor donor cells’ survival and expansion. 
            Taken together, the combination of gene and cell therapies may represent a type of novel 
effective approach for treating injured and diseased skeletal muscle. One such specific approach 
involves the use of the AAV-MPRO to inhibit MSTN in host muscle; it is certainly an approach 
that has the potential for the future with clinical applications of cell transplantation.   
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5.0  FOLLISTATIN IMPROVES SKELETAL MUSCLE HEALING 
5.1 INTRODUCTION 
Our group has identified anti-fibrotic agents which significantly enhance skeletal muscle healing 
after injury by antagonizing TGF-β1. These include suramin31, 32, γ-interferon 30, decorin 16, 28, 29, 
relaxin 148, 149, and losartan 27. Although much of the pathogenesis following skeletal muscle 
injury has been attributed to TGF-β1, we have recently reported that fibrosis is also caused by 
another agent that limits skeletal muscle healing, namely myostatin (MSTN) 127. MSTN is a 
primary negative regulator for the growth and development of fetal and postnatal skeletal muscle 
49, 73.  Several groups, including ours, have found that MSTN stimulates fibrosis in injured and 
diseased skeletal muscle 123, 127, 137 177. This is because the cell surface receptor to which MSTN 
predominantly binds-- activin type IIB cell surface receptor (ACVR2B)-- activates a downstream 
TGF-β-like signaling pathway 56, 64, 65. More interestingly, we find the reciprocity between 
MSTN and TGF-β1: TGF-β1 and MSTN reciprocally induce the expression of one another; 
blocking TGF-β1 signaling impairs MSTN’s biological activity, and vice versa 127. It suggests 
that TGF-β1 appear to act in synergy with MSTN to induce fibrosis in the skeletal muscle. 
In addition to impairing skeletal muscle healing by promoting fibrosis, MSTN also 
inhibits myofiber regeneration in diseases such as Duchene’s Muscular Dystrophy (DMD) 123 as 
well as after injury 127, 137.  Specifically in the former, mdx mice, an animal model of DMD, were 
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noted to undergo significantly more myofiber damage and less myofiber regeneration along the 
diaphragm when compared to MSTN knockout mdx mice (MSTN-/-/mdx) mice.123.  Similarly, 
following notexin-injury of the TA and laceration of the GM, there was a significantly greater 
regeneration and significantly less amount fibrosis among the MSTN-/- mice in comparison to 
WT controls 127, 137.  
To the end of developing therapies which can antagonize MSTN, research in this area has 
led to the discovery of a glycoprotein that neutralizes several proteins of the TGF-β family, 
namely follistatin (FLST).  FLST has been found to antagonize both MSTN in skeletal muscle 
and activin A in reproductive tissues, as well as neutralize several other proteins within the TGF-
β family80, 81 82. Several in vivo studies on FLST have further shown that the systemic 
administration of this agent directly inhibits MSTN and also reduces MSTN-induced muscle 
wasting 73 82, while FLST/OE transgenic mice exhibit a dramatic increase in muscle mass, much 
as is seen to occur in MSTN KO mice 56. 
In this study, we provided in vivo and in vitro data to support the development of FLST 
as a therapeutic agent for skeletal muscle injury and disease. Specifically, we hypothesize that 
FLST/OE transgenic mice will undergo more skeletal muscle regeneration and less fibrosis after 
laceration of the GM compared to WT controls. We next test that if skeletal muscle healing is 
superior in the FLST/OE mice compared to WT controls, then the muscle progenitor cells of the 
FLST/OE muscle will outperform cells of WT muscle, which is likely responsible for this 
enhanced healing. 
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5.2 METHODS 
5.2.1 Animal Model 
In accordance with our IACUC approval by the Children’s Hospital of Pittsburgh, we performed 
bilateral lacerations along the gastrocnemius muscle (GM) 28-31, 127, 149, as described at section 
3.2.7., of 16 male C57BL/6 wild-type (Jackson Laboratories, Bar Harbor, ME) and 16 male 
FLST/OE mice, each at 7-8 weeks of age, and harvested these muscles at 2 and 4 weeks after 
laceration (n=8 per group).  
5.2.1.1 Histology  
We quantified the percent fibrosis and muscle regeneration from each harvested muscles, as 
previously described127. Briefly, following cryosectioning of these tissues histological staining 
was performed with Masson’s trichrome kit (IMEB Inc., Chicago. IL); we then quantified the 
percent fibrosis with Northern Eclipse software (Empix Imaging, Inc., Cheektawaga, NY), which 
measures the area of fibrotic tissue along the sites of injury and divides this by the cross-
sectional area of tissue to calculate a percentage. For each limb, we obtained calculations from 
three representative and non-adjacent sections.  
            In order to evaluate skeletal muscle regeneration, we stained sections from each 
harvested muscle with Hematoxalin and Eosin (H&E), and quantified the smallest diameters of 
centro-nucleated myofibers, which represent regenerating muscle fibers, with Northern Eclipse 
software; we measured the diameters of over 350 non-consecutive centro-nucleated myofibers 
for each GM. 
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5.2.1.2 Immunohistochemistry 
Additionally, we performed immunohistochemistry to detect MSTN (red fluorescence) and 
collagen type IV (green fluorescence) expression along each injured GMs. We also targeted 
CD31, an endothelial cell marker, with immunohistostaining to monitor angiogenesis in injured 
muscle, and manually counted CD31-positive microvessels with Northern Eclipse software.   
5.2.1.3 MSTN immunostaining 
Frozen GMs were sectioned at 10 μM thickness and immunohistochemical analysis was 
performed to detect MSTN expression. Tissue sections were fixed in 4% formalin for 5 minutes 
followed by two 10-minute washes with PBS. The sections were then blocked with 10% HS for 
1 hour. Goat anti-MSTN (R&D Systems, Minneapolis, MN) primary antibody was separately 
diluted 1:100 in 2% HS and incubated with sections overnight at 4ºC. Sections were then washed 
three times with PBS and incubated with a secondary antibody, anti-goat IgG conjugated with 
biotin (1:200) (Vector Laboratories, Burlingame, CA), for 1 hour at room temperature (RT), 
followed by a PBS wash.  Finally, streptavidin conjugated with 555 (1:500) (Invitrogen, 
Carlsbad, CA) was applied to each section for an additional hour. Eventually, DAPI 
dihydrochloride (4', 6-Diamidino-2-phenylindole dihydrochloride; Sigma, St Louis, MO) was 
used to counterstain the nuclei. 
5.2.1.4 CD31 immunostaining 
To detect vascularity, we blocked the sections with 10% HS for 1 hour, and applied a rat CD31 
primary antibody (BD PharMingen, San Jose, CA) that was diluted 1:150 in 2% HS. This 
preparation was incubated for 1 hour at RT. The sections were then washed three times with PBS 
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and incubated with the secondary antibody, rabbit anti-rat IgG conjugated with 555 (Invitrogen), 
for 30 minutes. Finally, DAPI was used to stain the nuclei.  
5.2.2 Muscle Progenitor Cell Isolation and Transplantation into Skeletal Muscle 
5.2.2.1 Isolation of MPCs 
Using a modified preplate technique 113, 178, we isolated a fraction of MPCs with properties of 
low adhesion to collagen and long-term proliferation. We obtained five populations of WT 
MPCs from male neonatal C57BL/6J mice, as well as 7 populations of FLST/OE MPCs from 
male neonatal FLST/OE mice with a background of C57BL/6J mice as described at section 
4.2.5..  
5.2.3 Flow Cytometry 
In order to characterize WT and FLST MPC poulations, we utilized flow cytometry specific to 
the markers CD34, Sca-1 in both WT and FLST/OE MPCs to analyse the percentage of stem cell 
markers as previously described 113, 178 to examine whether FLST/OE MPCs contain more stem 
cells than WT MPCs. Briefly, cultured cells were trypsinized, centrifuged, and washed twice 
with PBS. We subsequently re-suspended our cell pellets, blocked them with 10% mouse serum 
(Sigma) for 10 minutes on ice and applied rat anti-mouse monoclonal conjugated antibodies 
(CD34-PE, Sca-1-APC; BD PharMingen) to incubate on ice for 30 minutes. Following this 
incubation period, we excluded nonviable cells by adding 7-amino-actinomycin D (7-AAD; 
Pharmingen) to each sample. Cells were then evaluated with a FACS Caliber flow cytometer 
(Becton Dickinson) and analyzed with CellQuest software (Becton Dickinson). 
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5.2.3.1 Cell transplantation 
After expanding MPCs in vitro, these cells were injected into the GMs of female mdx/SCID 
mices; these mice were bred by crossing Mdx (C57BL/10ScSn-Dmdmdx) and SCID (C57BL/6J-
prkdcscid/SzJ) mice (Jackson laboratory) at our institution’s animal facility. Approximately 3×105 
cells from each cell population were transplanted in each GM, for a total of 4 GMs among 
recipient female mdx/SCID mice. All mdx/SCID mice used were littermates, and all were 
sacrificed 2 weeks post-transplantation. The recipient GMs from these mice were harvested at 
this time, snap-frozen, and cyosectioned on a later date at thicknesses of 10 μM. Dystrophin 
immunostaining was performed to detect dystrophin positive myofibers formed from donor 
MPCs in dystrophic muscle as elaborated at section 4.2.7.. Dystrophin postive myofibers were 
then counted to assess the efficiency of cell transplantation in the skeletal muscle of mdx/SCID 
mice. 
5.2.4 Statistics 
All data are reported as the mean ± standard deviation (SD) or mean ± standard error of the mean 
(SEM), and data analyses have been performed with a Student’s t-test for comparisons between 
two groups as well as with a One-Way ANOVA for comparisons among three or more groups 
(SPSS Jandel Corporation). For all statistically significant differences observed after a One-Way 
ANOVA, the appropriate multiple comparison tests have been used to perform a post-hoc 
analysis. Statistical significance is considered for all p-values < 0.05; values marked with 
asterisks (*) and (**) represent Ρ < 0.05, Ρ < 0.01, respectively. 
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5.3 RESULTS 
5.3.1 Healing after Injury Is Enhanced in FLST/OE Skeletal Muscle 
5.3.1.1 Increased regeneration in the injured FLST/OE skeletal muscle 
Following laceration, the GMs from WT and FLST/OE mice regenerated as confirmed by 
visualizing centro-nucleated myofibers and variability of fiber size (i.e., fiber diameter) (Figure 
5-1A). Regarding the myofiber size, fiber diameters visualized at 7 days after laceration were 
small, ranging from 5-35 µm. (Figure 5-1B). Over time, however, the diameters of regenerating 
myofibers were increasing and myofibers gradually matured, with the mean diameter of 
FLST/OE myofibers being significantly larger than that of WT muscle fibers. Compared to WT 
mice, the mean fiber diameters for FLST/OE mice as measured at post-laceration days 7, 14, and 
30 were larger by approximately 25.3% (19.37 ± 0.80 vs. 15.46 ± 0.81; p < 0.01**), 31.6% 
(39.77 ±  3.69 vs. 30.22 ±  2.75; p < 0.01**), 32.5% (45.55 ±  3.03 vs. 34.38  ± 1.56;   p < 
0.01**), and 36.3% (64.36 ± 5.4 vs. 47.22 ± 3.49; p < 0.01**) respectively at 7, 14, 30 days, and 
1.5 years after GM laceration, when compared to WT mice (Figure 5-1C). The absolute 
differences (mean diameter of FLST/OE regenerating myofibers minus that of WT regenerating 
myofibers, green curve) in mean diameters of regenerating myofibers between WT and 
FLST/OE mice were also increasing (Figure 5-1C). Accordingly, healing muscles of FLST/OE 
mice compared to WT animals contain larger percentage of larger myofibers at each tome point. 
For example, at 7 days 49% of regenerating WT myofibers are smaller than 15 µm, on the 
contrary, 86% of regenerating  
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 Figure 5-1 Transgenic FLST/OE Skeletal Muscle Exhibited Better Muscle Regeneration after Injury 
Injured FLST/OE skeletal muscles showed accelerated regeneration as compared with WT counterparts. A, HE 
staining of cross section of injured WT and FLST/OE skeletal muscle at 7, 14, 30 days and 1.5 years after laceration 
injury. Myofibers and nuclei were stained in red and black, respectively. Regenerating myofibers are characterized 
by centralized nuclei. Black bar represents for 100 µm. B, Distribution of diameters of regenerating myofibers in 
WT and FLST/OE skeletal muscle 7, 14, 30 days, and 1.5 years after post-injury. Gray bars represent  myofibers 
from WT mice while black bars represent myofibers from FLST/OE mice. Moreover, the gray arrawheads indicates 
mean diameters of regenerating fibers in WT muscle, while black arrowheads indicates that in FLST/OE muscle. C, 
Quantitation of diameters of regenerating myofiber. The increases in the mean diameters of regenerating fibers in 
FLST/OE muscle over that in WT muscle is increasing. (* P < 0.05, ** P < 0.01) 
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FLST/OE myofibers are larger than 15 µm; at 14 days, 55% of regenerating myofibers of WT 
mice are smaller than 30 µm whereas 73% of regenerating myofibers of FLST/OE mice fall in to 
the category of 30 to 85 µm; at 30 days, 60% of regenerating myofibers of WT mice are smaller 
than 35 µm, while 73% of regenerating FLST/OE myofibers larger than 35 µm (Figure 5-1B). 
5.3.1.2 Decreased fibrosis in the injured FLST/OE skeletal muscle 
In addition to noticing differences in myofiber regeneration, we observed significant differences 
in the deposition of collagenous connective tissue after injury in each group of mice. Specifically 
at two weeks after laceration, fibrosis developed extensively in WT muscles, but relatively 
limited in FLST/OE muscles (Figure 5-2A). The percentage of fibrosis quantified at 2 weeks 
post-injury within these tissues, respectively, was 3.54% ± 1.71% and. 8.71% ± 2.36%, (p < 
0.01**) (Figure 5-2B). Compared to these values obtained at 2 weeks, our quantification 
analysis showed a reduction in fibrosis at 4 weeks among GMs of WT and FLST/OE mice 
(Figure 5-2 A); in spite of this, the relative fibrosis formation in WT GMs continued to be 
significantly larger than FLST OE GM (2.1 ± 1.1 vs. 5.57 ± 1.94; Ρ < 0.01**) at four weeks 
post-injury (Figure 5-2B).  However, fibrosis in both injured GMs of WT and FLST/OE mice 
disappeared at 1.5 years after injury (data not shown). 
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 Figure 5-2 The Muscle of FLST/OE Transgenic Mice Developed Less Fibrosis after Injury 
Fibrosis in injured FLST/OE muscle was reduced over injured WT muscle. Masson’s trichrome staining was 
performed on sections of injured FLST/OE and WT muscle (myofibers in red; fibrosis in blue). A, Representative 
images of injured FLST/OE and WT muscle at 14 and 30 days after injury. There is less fibrosis observed in injured 
FLST/OE muscle than WT muscle.  B, Injured FLST/OE muscles developed significantly less fibrosis than did 
injured WT muscles. (* P < 0.05, ** P < 0.01)          
5.3.1.3 Decreased MSTN and increased vascularity in the injured FLST/OE skeletal muscle 
Upon investigating how FLST enhances muscle healing, we found that, in vivo, apart from 
reported mechanism that FLST’s inhibition of MSTN via direct binding 56, 82, it also represses 
MSTN expression in injured FLST/OE muscle. This became apparent at two weeks after injury, 
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when we noted that FLST/OE muscle expresses less MSTN compared to WT muscle (Figure 5-
3A, B). Collagen IV (CollIV, green) immunostaining, staining for basal lamina, was used to 
trace the outline of myofibers. MSTN protein (red) mostly locates in the cytoplasm of 
regenerating fibers as indicated by CollIV and Centro-nuclei. However, some of MSTN-positive 
regenerating myofibers lacked the complete basal lamina. When measuring the area and density 
of MSTN signal in the injured muscles, we found that MSTN signals in the injured FLST/OE 
muscle were significantly less than observed in WT control. Moreover, it has been found that 
FLST stimulates angiogenesis both in vitro and in vivo 179, and a negative correlation has been 
reported between angiogenesis and fibrosis 124. These findings lead us to examine vascularization 
in the injured FLST/OE and WT muscles. We accessed the vascularity of injured FLST/OE and 
WT muscles at four weeks following laceration, and observed that FLST/OE muscles have a 
significantly larger number of CD31-positive microvessels along the zone of injury in 
comparison to their WT counterparts (Figure 5-3C, D).  This indicates that increased vascularity 
may at least be partially responsible for the improved muscle healing that is observed in 
FLST/OE mice. 
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 Figure 5-3 Decreased MSTN Expression and Increased Vascularity in Injured FLST/OE Skeletal Muscles 
A, Immunohistochemstry was performed to detect MSTN (fluorescence red) and collagen type IV (fluorescence 
green) expression in injured WT and FLST/OE muscle. Collagen type IV was used to locate basal lamina of 
myofibers including, necrotic, intact, and regenerating myofibers. MSTN-positive signals were seen with in some of 
regenerating myofibers with basal lamina and some of myofibers without basal lamina. Injured FLST/OE muscle 
contained less MSTN staining than did injured WT muscle. B, When we measured the relative area of MSTN 
positive, we found that there were significantly more MSTN signals detected in injured WT muscle than in injured 
FLST/OE muscle. C, CD31, an endothelial maker, was stained to monitor capillaries in injured muscle. D, There 
were a significantly more CD31 positive capillaries in injured FLST/OE muscle than that in injured WT muscle. (* 
P < 0.05, ** P < 0.01) 
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5.3.2 Comparison of WT and FLST/OE-MPCs 
5.3.2.1 In vivo muscle regeneration of MPCs  
Muacle progenitor cells (MPCs) are a population of long-term proliferating cells that regenerate 
the skeletal muscle of dystrophic mice more efficiently than myoblasts. Since injured FLST/OE 
muscles underwent better muscle regeneration than did WT controls, FLST/OE MPCs may 
accordingly be superior to WT MPCs in regenerating muscle. Using a preplate technique that our 
group has previously described, we isolated these cells from both WT mice and FLST/OE mice 
and compare their ability to regenerate skeletal muscle in dystrophic muscle. WT- and 
FLST/OE-MPC populations were injected into GMs of mdx/SCID mice, respectively with each 
population injected into 4 GMs.  Quantitation of engraftment with regard to the number of 
dystrophin-positive myofibers was performed to evaluate cell transplantation efficiency. Despite 
a high degree of variability in the WT- and FLST/OE-MPCs’ abilities to regenerate myofibers in 
vivo (Figure 5-4A), there is no WT-MPC population regenerating more than 400 dystrophin-
positive fibers, whereas, three of 7 FLST/OE populations regenerated 530 to 810 dystrophin-
postive fibers (Figure 5-4A); FLST/OE populations are significantly more successful at 
regenerating dystrophin-positive fibers. Specifically, whereas the WT-MPC population with the 
greatest amount of dystrophin-positive fiber regenerating was able to regenerate 400 fibers, 3 of 
7 FLST/OE populations regenerated between 530 to 810 fibers (Figure 5-4A). Overall 
FLST/OE-MPCs (n = 6) produced significantly larger muscle engraftment than did WT cells (n 
= 5) (485.5 ± 92.07 vs. 195.6 ± 65.375; Mean ± SEM; P = 0.023; t-test) (Figure 5-4B). Two 
representative dystrophin-postive engraftment-derived from FLST/OE- and WT-MPCs (784 vs. 
494 dystrophin-positive myofibers), respectively, are shown in Figure 5-4C.  
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 Figure 5-4 FLST OE MPCs Are Superior to WT MPCs in Regenerating Skeletal Muscle 
FLST/OE-MPCs regenerated skeletal muscle more efficiently than WT-MPCs, when transplanted into GMs of 
mdx/SCID mice. A, Quantitation of engraftment in terms of number of dystrophin-positive fibers regenerated from 
FLST/OE- and WT-MPC populations. B, The overall mean dystrophin-positive myofibers was significantly larger 
for FLST/OE MPCs (592.79 ± 154.9; Mean ± SEM; n = 7 FLST/OE-MPC populations; 4 muscles per population) 
than for WT-MPCs (195.6 ± 65.375; Mean ± SEM; n = 5 WT-MPC populations; 4 muscles per population; P = 
0.023**, t-test). C. Representive engraftments showed that transplanted MPCs regenerated dystrophin-postive 
myofibers (fluorescence red) within dystrophic muscle. FLST/OE-MPCs produced more dystrophin-positive 
myofibers than did WT-MPCs. (* P < 0.05, ** P < 0.01) 
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5.3.2.2 In vitro characterization of MPCs 
 
Figure 5-5 In Vitro Characterization of WT- and FLST/OE-MPCs 
Senven FLST/OE- and 5 WT-MPC populations were examined for Sca-1 expression, CD34 expression, and in vitro 
myogenic differentation. A, Histograms are showing wide variability in percentages of Sca-1+&CD34+ Sca-1+, and 
CD34+ cells among MPC populations. B. Quantitation revealed a significant increase in Sca-1+ fraction in 
FLST/OE-MPC population as compared with WT-MPC populations. C, Images on the left side are isotype control; 
images on the right side are representative images of flow plot showing that FLST/OE-MPC populations consist of 
large proportion of Sca-1+ cells than its WT counterpart (46.5% vs. 24%); D, Both FLST/OE- and WT-MPC 
populations underwent myogenic differentiation as labeled by MyHC (fluorescence red) and Dapi (blue). 
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To further characterize WT- and FLST/OE- MPCs, we use flow cytometry and 
immnocytochemistry to analyze the expressions of stem cells (i.e., Sca-1, CD34) and myogenic 
cell (Desmin) markers by these cells, respectively, and also determined proliferation and 
myogenic differentiation capacity of cell populations. From the histograms (Sca-1+&CD34, 
+Sca-1+, and CD34+) in Figure 5-5 , the heterogeneous profile of stem cell markers is apparent; 
cell populations within either FLST/OE or WT group exhibit great variation in the percentages of 
stem cell marker positive cells. Compared to WT-MPC populations, however, FLST/OE 
populations possess a significant larger percentage of cells that are positive for Sca-1 (Figure 5-5 
A.B). The representative images of flow plot showed that one FLST/OE-MPC and one WT-MPC 
population contained 46.5% and 24% Sca-1 positive cells, respectively (Figure 5-5 C). In the 
low serum containing medium, both FLST/OE- and WT-MPC cells were capable of 
differentiating and fusing into myotubes as labeled by myosin heavy chain (MyHC) (Figure 5-5 
D). The percentage of desimin-positive cells, proliferation, and myogenic differentiation capacity 
were compared between FLST/OE- and WT- MPC population, however, due to a broad 
variability, no significant difference was found (data not shown).  
5.4  DISCUSSION 
In this study, we show that the skeletal muscle healing of GMs among FLST/OE mice is superior 
to that of the GMs among WT mice. Specifically, the mean diameter of regenerating myofibers 
in injured FLST/OE muscle remain significantly larger than WT counterparts, while fibrosis was 
significantly lower in the former; these results are comparable to those that we previously 
obtained for injured MSTN-/- GMs 127.  There are several explanations for this that can be 
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derived from our results. These include the impact that FLST has on a) downregulating the 
expression level of MSTN and augmenting vascularity in injured muscle, b) enhancing the 
ability of MPCs to regenerate skeletal muscle. Although we will discuss these events 
individually, we highlight that they are not mutually exclusive of one another, but rather, 
illustrate how FLST can synergistically promote healing through each of these processes. 
5.4.1 Mechanism Involved in the Reduced Fibrosis in the Injured FLST/OE Muscle 
TGF-β1 expression in injured skeletal muscle is time dependent; it peaks at 3-5 days and 10-14 
days post-injury 16, 26, 180. The latter event appears to associate with the formation of fibrosis and 
ineffective muscle regeneration 16. Blocking the second peak of TGF-β1 by administrating 
antifibrotic agent at 14 days post-injury led to histological and physiological improvement of 
injured muscle 16, 28-32, 148, 149. Coincidently, our in vivo studies show significant decrease in 
MSTN immunostaining among injured FLST/OE GMs at 2 weeks after injury. Similar to our 
previous findings 127, some small regenerating myofibers without basal lamina were strongly 
MSTN signal positive in the injured WT and FLST/OE GMs. Li et al reported that some 
regenerating myfibers appeared to degrade and transform into myofibroblasts to aggravate 
fibrosis in the injured skeletal muscle 16.  If it is the case, these MSTN-positive, lacking basal 
lamina regenerating fibers may represent a transitional status of regenerating myofibers that are 
undergoing the differentiation process into myofibroblasts. The decrease in the amount of MSTN 
at the injured site probably partially account for reduced fibrosis in injured FLST/OE muscle for 
following reasons: a) there is less MSTN available to trigger fibrosis in injured muscle, b) due to 
the fact that TGF-β1 request MSTN’s synergistic action to induce fibrosis in muscle 127, reduced 
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amount MSTN may reduce TGF-β1’s pro-fibrotic effect. This result also indicates that, in 
addition to directly inhibiting MSTN, FLST may further decrease the expression of this protein. 
Furthermore, while prior reports indicate that FLST upregulates angiogenesis both in vivo 
and in vitro, we show that there is significantly more vascularization occurring in injured 
FLST/OE muscle compared to WT controls 179. As FLST can be expressed by endothelial cells 
that are activated but not quiescent, these data on the impact of FLST on the cell cycle and 
angiogenesis are certainly 181. It is thereby also noteworthy to point out that angiogenesis 
correlates with an increase in muscle regeneration and a decrease in fibrosis 124. Presently, 
however, there is insufficient evidence to indicate whether FLST directly stimulates angiogenesis 
in injured skeletal muscle. 
5.4.2 Cellular Mechanism by Which FLST Promotes Skeletal Muscle Regeneration after 
Injury 
The development of skeletal muscle during embryogenesis and its regeneration after trauma or in 
the setting of skeletal muscle disease is largely occurs from the differentiation of satellite cells 
into myofibers 182-184. Adult satellite cells enter cellular quiescence within a niche between the 
basal lamina and scarcolemma of myofibers, thereby forming a pool of myogenic progenitor 
cells 185. In response to muscle trauma and during disease, these cells are activated to re-enter the 
cell cycle, migrate from the basal lamina to the zone of injury, and undergo asymmetric 
divisions.  A preponderance of daughter cells are committed to differentiate and fuse into 
multinucleated myofibers, while a small portion of self-renewing cells replenish the reservoir of 
satellite cells by re-entering quiescence.  
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MSTN inhibits satellite cell self-renewal by downregulating the G1 to S progression and 
retaining satellite cells in a quiescent status 47, 186; inversely, MSTN-/- skeletal muscle  comprise 
more satellite cells than WT counterparts, likely resulting from an increase in proliferation and a 
delay in myogenic differentiation among adult MSTN-/- satellite cells 47.  Based on this 
information, we sought to determine the impact of FLST on MPCs.  MPCs are a heterogeneous 
population consisting of myoblasts, satellite cells, progenitor cells, and stem cells, which were 
isolated from the GMs of both FLST/OE and WT mice with the modified pre-plate technique. As 
the number of dystrophin-positive myofibers is a standard by which the regenerative efficiency 
of transplanted cells in dystrophic skeletal muscle is measured, 125, 126, 128, we performed such a 
comparison between both populations of MPCs. After injecting MPCs isolated from FLST/OE 
and WT mice into the GMs of mdx/SCID mice, we found that overall, FLST/OE-MPC 
populations regenerate significantly more dystrophin-positive myofibers; however, not all 
FLST/OE-MPC populations outperformed their WT counterparts. Variation regarding to the 
regenerative capacity of both types cells is remarkable. Specifically, dystrophin-positive fibers 
regenerated from FLST/OE-MPC population vary from 200 to 1398, while those produced from 
WT-MPC populations varying from 27 to 400. The increase in regenerative capacity of 
FLST/OE MPC populations probably partially accounts for the better regeneration in the injured 
FLST/OE muscle than WT muscle.  These finding may help researchers to develop optimal cell 
population for cell-based therapy to Duchene Muscular Dystrophy, a lethal sex-linked recessive, 
muscle-wasting disease stemmed from a mutation of the dystrophin gene. For instance, transplantation 
of muscle cells carrying FLST transgene into the dystrophic muscle may enhance the success of 
cell transplantation in comparison to that of normal muscle cells.  
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We further investigate whether marker profile, proliferation rate, and myogenic 
differentiation capacity of MPCs can render a clue to their in vivo performance. While it is 
important to note that the regenerative ability of each MPC populations varies, this was true for 
myoblasts, satellite cells, progenitor cells, and stem cells collectively 126. Our group previous 
found that regenerative capacity of muscle primary cells appears to be negatively related to the 
level of their in vitro myogenic commitments when they compared different fractions among the 
same muscle primary cell population 128. Moreover, they further showed that the CD34+ fraction 
of MPCs showed significantly improvements in dystrophin restoration after transplanted into 
dystrophic muscle,  when compared to CD34- fraction of the same MPC population 128. 
Nevertheless, these criteria can not be applied to this current study, since we are comparing cell 
performances among MPC populations isolated from different mice.  We instead found that 
MPC populaltions isolated from both types of mice exhibited a broad heterogeneity of cell 
surface markers, proliferation rate, and myogenic capacity in vitro. In spite of this heterogeneity, 
the FLST/OE-MPC populations contain a significantly larger percent of Sca-1+ than WT control. 
However, our results suggest that the degree of in vitro myogenic commitment, proliferation rate, 
and expression levels of stem cell, and myogenic marker can not be use to predict cell’s in vivo 
performance among different cell populations. It is consistent with data collected by others in our 
group 126. Neither myogenic and stem cell marker profile of cells, nor in vitro differentiation 
capacity of cells does appear to correspond to their performance in regenerating dystrophin-
positive myofibers 126.  
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5.5 CONCLUSION 
We conclude that FLST has great therapeutic potential for the treatment of injured skeletal 
muscle, as it enhances skeletal muscle healing by inhibiting MSTN. This is illustrated through 
experiments in which there is an increase in skeletal muscle regeneration and a decrease in 
fibrosis along the zone of injury among FLST/OE mice, as well as in experiments where MSTN 
expression is down-regulated in FLST/OE muscles after injury. As expected from these findings, 
we show that injured FLST/OE muscles undergo significantly more CD31 positive capillary-like 
structure as compared to controls, and that FLST/OE MPCs have a superior regenerative 
capacity compared to WT-MPCs.  
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6.0  OVERALL CONCLUSION 
Theoretically, the therapeutic strategy for treating injured skeletal muscle includes down-
regulating muscle degeneration, inflammation, up-regulating regeneration, and inhibiting 
fibrosis. The goals of our projects were to enhance our understanding of the mechanisms 
involved in the injured skeletal muscle, and to promote the development of biological approaches 
to improve skeletal muscle healing. We have found that MSTN, a negative regulator of adult 
skeletal muscle growth, contributes to the formation of fibrosis in injured skeletal muscle. MSTN 
does not independently induce fibrosis in the skeletal muscle; instead, MSTN and TGF-β1 
appear to synergistically stimulate fibrosis. The following is a list of supporting facts which 
demonstrate this synergy: 1) MSTN and TGF-β1 share a TGF-β-like signal transduction pathway 
64, 65; 2) MSTN and TGF-β1 reciprocally stimulate myoblasts to express one another; and 3) 
Blocking the TGF-β1 signal pathway compromises MSTN’s activity, and vice versa; moreover, 
decorin, which has been known to block fibrosis by inhibiting TGF-β1, also counteracts the 
activity of MSTN. Based on this background knowledge and our recent findings, we used MSTN 
as a therapeutic target to develop biological approaches to improve skeletal muscle healing after 
injury by inhibiting the action of MSTN.  
 We found that both MPRO and FLST can effectively inhibit MSTN, which results in 
improved skeletal muscle healing after injury by enhancing muscle regeneration and inhibiting 
fibrosis. Blocking MSTN signaling can significantly enhance the regenerative capacity of donor 
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muscle cells transplanted into the skeletal muscles of mdx/SCID mice, by either blocking MSTN 
expression in the donor cells, which can be done by utilizing muscle progenitor cells (MPC’s) 
isolated from MSTN-/- mice or from FLST/OE mice, or by blocking MSTN expression in the 
recipient muscle. In conclusion, our results have elucidated that MSTN is an effective 
therapeutic target for the injured and diseased skeletal muscle, and demonstrated that MPRO and 
FLST are capable of neutralizing MSTN and improving skeletal muscle healing. Nevertheless, 
several questions still need to be addressed in the future. 
6.1 FUTURE DIRECTION AND LIMITATION 
6.1.1 Determine If Blocking MSTN in Injured Skeletal Muscle Leads to Functional 
Recovery 
In the current study we used two histological variables to evaluate the quality of muscle healing, 
the mean diameter of regenerating myofibers and the percentage of fibrosis. Our results 
suggested that blocking MSTN signaling improved the healing of injured skeletal muscle when 
compared to control, as indicated by the enhancement of regeneration and reduction of fibrosis; 
however, physiological improvements have not yet been determined. It is important to real ize 
that histological improvements do not necessarily correlate with physiological performance. Our 
group has shown that both insulin-like growth factor–1 (IGF-1) and decorin are capable of 
enhancing skeletal muscle healing histologically and physiologically. When IGF-1 and decorin 
were used in combination on injured skeletal muscle, a further improvement was seen 
histologically, but not functionally 28. Another group reported that MSTN blockade increased 
fiber size, muscle mass, and absolute force, but histopathologically degenerative foci and serum 
  98
creatine kinase levels remain unchanged,  in a murine model of limb-girdle muscular dystrophy 
2C 162. The reasons for the disparity between histological and physiological improvement remain 
unclear; although, several studies demonstrated that inhibiting MSTN improves muscle function 
and strength in mdx mice 77, 123, 151, 157.  Future experiments, should utilize physiological testing, 
such as specific peak force and tetanic force as described previously 28, 29 to investigate whether 
blocking MSTN promotes the functional recovery of injured skeletal muscle.  
6.1.2 Correlation between Angiogenesis and Improved Muscle Healing 
Our data demonstrated an increase in the number of CD31 positive capillary-like structures in the 
injured skeletal muscle in MSTN-/- mice, AAV-MPRO transduced muscle, and FLST/OE mice. 
These muscles also showed improvement in skeletal muscle healing when compared to their WT 
counterparts, which suggests that MSTN appears to inhibit the in-growth of CD31 positive 
capillary-like structures in the injured skeletal muscle and that MPRO and FLST block MSTN 
thereby stimulating angiogenesis. In future studies, we need to investigate how MSTN regulates 
endothelial cell proliferation, migration, and synthesis of vascular endothelial growth factor 
(VEGF). Using an in vitro angiogenesis model, we can investigate whether MSTN has the ability 
to down-regulate endothelial cells to form von willebrand factor (vWf)-positive capillary-like 
tubular networks on three dimensional (3D) collagen gel, which will greatly help us to 
understand the role of MSTN in angiogenesis 187, 188.  Also in future studies, we will develop 
techniques to monitor 3D vasculature in the skeletal muscle utilizing a commercially available 
contrast agent (Fenestra VC™) to quantify vascularization in live animals with our micro 
computed tomography scanner (VivaCT)). Alternatively, we could use a barium-gelatin mixture 
as the contrast agent to measure vascularization post-mortem. Micro-CT data can be used to 
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monitor the vascular supply and indirectly measure the area of fibrosis (non-vascularized area) 
and can be correlated with histological findings. The evidence that MSTN-/- mice develop a 
more vascularized network in injured skeletal muscle than WT controls will strongly support the 
hypothesis that blocking MSTN enhances angiogenesis in skeletal muscle after injury.  
6.1.3 Limitation 
To the best of our knowledge, MSTN is mainly expressed in the skeletal and cardiac muscle 49. If 
it is the case, our findings that MSTN is a fibrotic stimulator, and that MPRO and FLST inhibit 
MSTN, thereby reducing fibrosis in the injured skeletal muscle may not be applied in other 
tissues. That is, we don’t suggest that our results will be applied to different organs and tissues 
such as lung, liver, kidney, and skin, which may not express MSTN. Surprisingly, MSTN 
blockade appears not to attenuate cardiac fibrosis in the mdx mice 189. Nevertheless, more 
evidence showed that MSTN may promote fibrosis in other tissues besides skeletal muscle 190, 
191. MSTN stimulates synthesis of collagen and TGF-β1, and phosphorylaltion of Smad2/3 in 
C3H 10T1/2 cells, a multipotent mesenchymal mouse cell line 190; FLST blocks MSTN’s fibrotic 
effects on C3H 10T1/2 cells 190. Moreover, MSTN appears to play a role in the Peyronie's 
disease (PD) characterized by deformity and painful erection 191, in which the cavernous body of 
the penis is encircled by patches or strands of dense fibrous tissue, which mainly mediated by 
TGF-β1. The expression level of MSTN was upregulated in the myofibroblasts of the PD plaque 
as compared to normal tunica albuginea (TA), and MSTN cDNA injected in the normal (TA) led 
to a fibrotic PD plaque and aggravated the TGFβ1-induced lesion 191. Take together, the fibrotic 
role of MSTN in the different organs and tissues warrants further investigation.  
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APPENDIX A 
DIAMETER ANALYSIS OF REGENERATED MYOFIBERS USING NORTHERN 
ECLIPSE 
A.1 PHOTOGRAPH FOR SECTIONS WITH IMMUNOHISTOCHEMICAL STAIN 
1. Open Northern Eclipse software. 
2. Go to View to select User Window  opening “merge window” 
1) to select colors from “merge window” checking “green” (basal lamina) 
and “blue” (nuclei) box 
2) to chose loop 
3. Select 10x objective lens from fluorescence microscope, focusing and choosing green and 
blue filter subsequently to take merged image (green and blue) 
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A.2 ANALYSIS OF REGENERATED MYOFIBER DIAMETER 
1. Go to View to select View Options 
1) Bin (new bin with limited condition: Check “Include these  
objects” to check new bin, uncheck Default) 
 
2) Data: Chose right parameters such as “object Count”, “Minimum axis   
diameter” 
2.    Go to Process to choose Conversions to convert image to 8 bit grayscale 
3. * Threshold (Monochrome threshold for 8 bit gray image) 
4.   Go to Measure > Selection Tool to select the area that you want to measure  
5.   Go to View > Data to set “Objects partially inside selection” are “Excluded from selection” 
6.   Optimize condition using New Bin, based on value of measurement.  
7.   View> View Options > Selection  to set Object Marker as yellow dot 
8.   Click on Measure button in Toolbar 
9.   LOG to DDE to export data to Excel spreadsheet 
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 Appendix Figure A. 1 Collagen IV immunohistochemistry stain (green) for basal lamina of 
regenerated myofibers (A); Image threshold in 8 bit grey (B) using Northern Eclipse 
software. 
 
 
Appendix Figure A. 2 Measurement of minimal diameter of regenerated myofibers. Yellow 
dots in the center of myofiber mean the selected myofibers 
Note: 3* the function in this application is used to distinguish the basal lamina of 
myofibers from background. The value of intensity corresponding to the grayness varies fro 0 to 
255. When we alter the values, the selected pixels (basal lamina) are shown in red/white, while 
unselected pixels (background) are indicated in cyan/black. 
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APPENDIX B 
PROCEDURES FOR QUANTIZATION OF FIBROSIS FORMATION USING 
NORTHERN ECLIPSE 
Images of injured muscle stained with Masson’s Trichrome stain were photographed with a 
microscope digital camera system using Qcapture software.  
B.1 TAKING BRIGHTFIELD IMAGE AND MASSON'S TRICHROM STAINING 
1. Move the beam under camera to the middle position (which should be  
     moved to the left side for fluorescence picture). 
2. Open Qcapture software 
3. Chose a blank area from slide for white balance 
4. Move slide to find area of interest 
5. Go Acquire and open Living Preview 
6. Use Camera Setting in Acquire to adjust color of picture 
7. Use Snap in Acquire to take picture 
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       Notes: Images of entire cross-sectional muscles were taken under 2x objective lens to so that 
entire muscle section was included.  
B.2 ANALYSIS OF FIBROSIS FORMATION USING NORTHERN ECLIPSE 
1. Open Northern Eclipse 
2. Open your file and use Zoom to adjust size of image (Typically, 50% of image is chosen) 
3. Go Threshold  (color (24 bit) thresholding) to change RGB model to HSV Model (Hue, 
Saturation, Value). The muscle fibers turn to be grey, while the collagenous tissue remains blue. 
And then adjust Hue, Saturation, Value separately so that the collagenous tissue area is 
identical to that in original image (Appendix Figure B.1).   
5. Go to Measure, Selection Tool , and then choose Trace Tool to draw a line along the edge of 
the muscle cross section. Measurement area is cut by selection, meaning that only area selected 
was measured (Appendix figure B.2) 
6. Use Square tool to select bands of interest 
7. Click on Measure button in Toolbar.  
8. LOG to DDE to export data to Excel spreadsheet 
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 Appendix Figure B. 1 Image of injured muscle cross section (A), same image in HSV model 
 
 
Appendix Figure B. 2 Measurement of scar tissue area (9.3426%) 
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Note:  
Threshold is used to distinguish targeted objects from the rest of image by specifying 
range(s) of values such as hue, saturation, brightness. 
HSV is a distinct color space from RGB (red, green, blue), which is non-linear 
transformation of RGB. Compared to RGV, HSV is more representative for the way 
that humans perceive color.  
Hue refers to the color type arranging from red through the yellows, green, blues, and 
violets: 
? Ranges from 0-360 (but normalized to 0-359 in Northern Eclipse) 
• Saturation indicates the vibrancy of the color: 
? Ranges from 0-100% (but normalized to 0-255 in Northern Eclipse) 
? The saturation of a color is correlated to the “grayness”. When the 
saturation of a color is low, correspondingly, the faded color will appear as 
a result of low grayness. This function is use to define desaturation as the 
qualitative inverse of saturation. 
• Value depicts the brightness of color: 
? Ranges from 0-100% (but normalized to 0-255 in Northern Eclipse) 
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 Appendix Figure B. 3 HSV color space as a color wheel 
Http://en.wikipedia.org/wili/HSV_color_space 
 
As shown in Appendix Figure B.3 the hue is illustrated by a circular region; Saturation 
and value are stood for by a triangle region with a vertical axis indicating saturation and 
horizontal axis representing value. When we do threshold, we began with selecting the hue 
(color) from the circular region, then pick the optimal saturation and value from the triangular 
area. The resultant result is shown in appendix Figure B. 1-B. 
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